var title_f26_50_27424="Endocrine glands PI";
var content_f26_50_27424=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F67279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F67279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    Endocrine glands",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 556px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows the location of the adrenal glands, hypothalamus, and pituitary.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_50_27424=[""].join("\n");
var outline_f26_50_27424=null;
var title_f26_50_27425="Lymph nodes female";
var content_f26_50_27425=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Lymph node groups in women",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 584px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The green dots indicate the location of lymph nodes, which are found throughout the body.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_50_27425=[""].join("\n");
var outline_f26_50_27425=null;
var title_f26_50_27426="Trypan blue: Drug information";
var content_f26_50_27426=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trypan blue: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/60/11203?source=see_link\">",
"    see \"Trypan blue: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F232281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      MembraneBlue&trade;;",
"     </li>",
"     <li>",
"      VisionBlue&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F232291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ophthalmic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F232282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cataract surgery:",
"     </b>",
"     Trypan blue 0.06% (VisionBlue&reg;): Apply onto anterior lens capsule using a blunt cannula",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Vitrectomy surgery:",
"     </b>",
"     Trypan blue 0.15% (MembraneBlue&trade;): May apply to epiretinal membranes using a blunt cannula or may inject directly in a balanced salt solution-filled vitreous cavity",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F232287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cataract surgery:",
"     </b>",
"     Topical: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F232283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F232273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MembraneBlue&trade;: 0.15% (0.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VisionBlue&reg;: 0.06% (0.5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F232265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F232275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trypan blue 0.06% (VisionBlue&reg;): To minimize dilution of the dye (trypan blue) by the aqueous, an air bubble should be injected into the anterior chamber of the eye after opening the eye, but prior to application of trypan blue. Irrigate with balanced salt solution to remove excess dye.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trypan blue 0.15% (MembraneBlue&trade;): If applying to epiretinal membranes, must perform a fluid-air exchange prior to injection of trypan blue to prevent aqueous solution of the dye; immediately remove all excess dye following injection. If injecting directly into a balanced salt solution filled-vitreous cavity, wait 30 seconds following injection (sufficient staining is achieved after 30 seconds), then remove all excess dye.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F232274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Staining of anterior capsule of the lens as an aid during cataract surgery; staining of the epiretinal membranes as an aid during ophthalmic surgical vitrectomy procedures, facilitating tissue removal",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F232289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ocular: Posterior lens staining, vitreous face staining; staining may last up to 1 week",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F232277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to trypan blue or any component of the formulation; use when a nonhydrated (dry state), hydrophilic acrylic intraocular lens (IOL) insertion is planned (potential for the dye to be absorbed by and stain the IOL)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F232267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Remove excess dye after use to prevent excessive staining.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F232271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F232278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects, increased fetal mortality, and decreased fetal weight were observed following systemic use in animal studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F232284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F17969771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if trypan blue is excreted in breast milk. The manufacturer recommends that caution be exercised when administering trypan blue to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (MembraneBlue Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15% (0.5 mL): $114.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (VisionBlue Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.06% (0.5 mL): $50.40",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12992802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Oftablu (IT);",
"     </li>",
"     <li>",
"      VisionBlue (NL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F232266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An acid di-azo group dye which selectively stains connective tissue structures in the human eye",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10331 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-AD9E7E195A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_50_27426=[""].join("\n");
var outline_f26_50_27426=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232281\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232291\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232282\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232287\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232283\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232273\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232265\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232275\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232274\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232289\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232277\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232267\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232271\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232278\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232284\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F17969771\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324045\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12992802\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232266\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10331\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10331|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/60/11203?source=related_link\">",
"      Trypan blue: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_50_27427="Anterior acetabular wall fracture";
var content_f26_50_27427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Anterior acetabular wall fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 414px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) On the anteroposterior (AP) view, the disruption of the iliopectineal line is seen in two locations.",
"    <br>",
"     (B) The obturator oblique view confirms this disruption, but shows that the femoral head remains congruent against the anterior wall.",
"     <br>",
"      (C) The iliac oblique view shows that the posterior border of the acetabulum is intact, and that the ilioischial line disruption seen on the AP view is due to a fragment from the quadrilateral surface. (Courtesy of Michael Stover, MD.)",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Moed BR, Reilly MC. Lower extremity: Acetabulum fractures. In: Rockwood and Green's Fractures in Adults,&nbsp;7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"      </div>",
"      <div class=\"contractual\">",
"       <br/>",
"       <a href=\"file://www.lww.com\">",
"        file://www.lww.com",
"       </a>",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_50_27427=[""].join("\n");
var outline_f26_50_27427=null;
var title_f26_50_27428="HAPE CT";
var content_f26_50_27428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    HAPE CT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 376px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With HAPE, chest CT often reveals patchy alveolar infiltrates, predominantly in the right central hemithorax, which become more confluent and bilateral as the illness progresses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott A Gallagher, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_50_27428=[""].join("\n");
var outline_f26_50_27428=null;
var title_f26_50_27429="Monitoring and surveillance of hemodialysis arteriovenous fistulas to prevent thrombosis";
var content_f26_50_27429=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Monitoring and surveillance of hemodialysis arteriovenous fistulas to prevent thrombosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/50/27429/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/50/27429/contributors\">",
"     Michael Allon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/50/27429/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/50/27429/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/50/27429/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/50/27429/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/50/27429/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/50/27429/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/50/27429/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/50/27429/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodialysis requires access to blood vessels capable of providing rapid extracorporeal blood flow. These requirements are currently best met by both primary arteriovenous (AV) fistulas and synthetic grafts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23816?source=see_link\">",
"     \"Arteriovenous fistulas and grafts for chronic hemodialysis access\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues surrounding monitoring and surveillance of hemodialysis AV fistulas in the attempt to prevent thrombosis and access failure are presented in this topic review. Similar issues for hemodialysis AV grafts are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/38/615?source=see_link\">",
"     \"Monitoring and surveillance of hemodialysis arteriovenous grafts to prevent thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROSPECTIVE MONITORING AND SURVEILLANCE FOR STENOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Practically all clotted fistulas have an underlying stenosis. This was shown in a series of 93 consecutive clotted fistulas in which 100 percent had an underlying stenotic lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27429/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Direct visualization of the vascular access using angiography is the gold standard to diagnosis stenosis. However, noninvasive assessment is preferred for efficient screening to first identify those fistulas most likely to be stenotic. Only those with sufficiently abnormal tests would then require diagnostic angiography and, if indicated, preemptive angioplasty.",
"   </p>",
"   <p>",
"    Currently, surveillance of hemodialysis AV fistulas is performed by both clinical assessment and noninvasive methods to evaluate graft flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical monitoring refers to assessments that can be performed by physical examination of the access or by using readily available information that is collected in the course of treating dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27429/abstract/2\">",
"     2",
"    </a>",
"    ]. Clinical monitoring falls into the following three broad categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormalities of physical examination, such as absent thrill, discontinuous bruit, or edema distal to the fistula.",
"     </li>",
"     <li>",
"      Problems noted during the dialysis session, such as difficulty with cannulation, aspiration of clots, inability to achieve the target dialysis blood flow, or prolonged bleeding from the needle puncture sites.",
"     </li>",
"     <li>",
"      An unexplained (&gt;0.2 units) decrease in the delivered dialysis dose",
"      <span class=\"nowrap\">",
"       (Kt/V)",
"      </span>",
"      on a constant dialysis prescription.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A paucity of evidence exists regarding the value of clinical monitoring to detect stenosis in patients with hemodialysis AV fistulas. Clinical monitoring may be less useful in fistulas than in grafts, although the evidence is conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study evaluated 543 fistulograms in 358 grafts and 185 fistulas, which were prompted by abnormalities of clinical monitoring detected by dialysis nurses [",
"      <a class=\"abstract\" href=\"UTD.htm?26/50/27429/abstract/3\">",
"       3",
"      </a>",
"      ]. The positive predictive value for greater than 50 percent stenosis was only 39 percent for fistulas, as compared with 69 percent for grafts.",
"     </li>",
"     <li>",
"      The findings of a pre-procedure physical examination were compared with results via angiography in a prospective trial of 142 consecutive patients with AV fistula dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?26/50/27429/abstract/4\">",
"       4",
"      </a>",
"      ]. The sensitivity and specificity of physical examination of the fistula were 92 and 86 percent for outflow stenosis and 85 and 71 percent for inflow stenosis, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?26/50/27429/abstract/4\">",
"       4",
"      </a>",
"      ]. However, examinations were performed by a nephrologist who was experienced in clinical access assessment, and it is unclear whether comparable results can be obtained by less-experienced clinicians or dialysis nurses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, clinical monitoring, most commonly by dialysis nurses, is less accurate with fistulas than grafts to accurately detect stenoses. This may be due in part to the lower frequency of stenosis in fistulas than in grafts. Thus, negative fistulograms are not uncommon among patients referred for the study based upon abnormal clinical monitoring.",
"   </p>",
"   <p>",
"    Some experts suggest that the following two clinical clues are particularly suggestive of underlying stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27429/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Failure of the fistula to collapse when the arm is elevated.",
"     </li>",
"     <li>",
"      Lack of pulse augmentation when the outflow vein is occluded transiently. This may be more useful in relatively new fistulas than in older fistulas that are relatively more rigid.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is unclear whether the accuracy of these tests in detecting stenosis is reproducible in other dialysis centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;To overcome the limitations of clinical monitoring, a number of surveillance methods for stenosis have been developed. Unlike clinical monitoring, each of these surveillance methods requires specialized equipment or specially trained staff. The advantage of access surveillance is that it is therefore likely to be performed more consistently and reproducibly than clinical monitoring. However, implementing an access surveillance program requires additional cost, which is not currently reimbursable in the United States. Thus, to justify this added expense, these approaches must demonstrate that their use is associated with improved patency.",
"   </p>",
"   <p>",
"    All fistula surveillance methods rely upon the observation that progressive stenosis results in an increase in intrafistula pressure (normalized for systemic blood pressure)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a decrease in access blood flow.",
"   </p>",
"   <p>",
"    The three major types of access surveillance are [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27429/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intra-access blood flow monitoring",
"     </li>",
"     <li>",
"      Static dialysis venous pressure",
"     </li>",
"     <li>",
"      Duplex ultrasound",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Flow monitoring is the optimal surveillance method for fistula stenosis due most likely to the fistula being a low pressure system. In a randomized prospective study, the positive predictive value of flow monitoring for fistula stenosis was twice as good as that obtained with clinical monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27429/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal threshold of access flow for detecting stenosis appears to be lower (approximately 450 to 500",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    in fistulas than in grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27429/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In one study, for example, an access flow of 465",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    was associated with a sensitivity and false positive rate of 0.89 and 0.32, respectively, for predicting fistula stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27429/abstract/6\">",
"     6",
"    </a>",
"    ]. We use an access flow rate less than 500",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    as suggestive of underlying stenosis.",
"   </p>",
"   <p>",
"    Static dialysis venous pressures have a lower positive predictive value for stenosis in fistulas, as compared with grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27429/abstract/9\">",
"     9",
"    </a>",
"    ]. We do not consider static dialysis venous pressures to be useful for fistulas. There are only very limited data concerning the use of duplex ultrasonography in fistulas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     K/DOQI recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;For monitoring and surveillance of fistulas, the 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    work group prefer the following [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27429/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Direct flow measurements",
"      </strong>",
"     </li>",
"     <li>",
"      Physical findings suggestive of stenosis. These include persistent arm swelling, prolonged bleeding after needle withdrawal, collateral veins, and altered features of the pulse or thrill.",
"     </li>",
"     <li>",
"      Duplex ultrasonography",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    work group also suggest that it is acceptable to use recirculation (via a non-urea-based dilutional method) or static pressures (either direct or derived) for surveillance of fistulas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EFFECTIVENESS OF ACCESS SURVEILLANCE ON FISTULA THROMBOSIS AND ACCESS SURVIVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;A paucity of evidence exists concerning the effectiveness of stenosis surveillance for fistulas. Because thrombosis is much less common in fistulas than in grafts, it is more difficult to demonstrate a reduction of thrombosis with stenosis surveillance.",
"   </p>",
"   <p>",
"    Observational and non-randomized studies are conflicting concerning any benefits with access surveillance on fistula thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27429/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. By comparison, the only randomized trial reported a significantly lower fistula failure rate in patients undergoing flow monitoring with preemptive angioplasty than in patients without surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27429/abstract/14\">",
"     14",
"    </a>",
"    ]. In this trial, 79 patients with fistulas with a proven stenosis were randomly assigned to preemptive angioplasty or surgical revision or to a control group in which intervention was deferred until there was a decrease in",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    or the fistula clotted. Cumulative fistula survival was significantly higher in the intervention group. However, these findings may be limited because it was a single center study and the type of intervention may be important, as the same group reported better patency with surgical revision than with angioplasty. Further study may be required to better understand the role of flow monitoring in patients with fistulas.",
"   </p>",
"   <p>",
"    In general, the role for surveillance of hemodialysis fistulas is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ROLE OF FISTULOGRAMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic contrast studies can define the arterial and venous portions of the hemodialysis fistula to the level of the superior vena cava. Although the fistulogram remains the gold standard for the detection of venous stenoses [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27429/abstract/15-19\">",
"     15-19",
"    </a>",
"    ], the expense and difficulty of performing this procedure limit its utility as a screening test.",
"   </p>",
"   <p>",
"    It is, however, the definitive study prior to intervention. In addition to documenting the anatomy of the fistula, the fistulogram can be used in association with percutaneous transluminal angioplasty and stent placement, and can serve as a guide for surgical revision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OUR APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently, the dialysis staff at our center performs physical examination of the fistula weekly, and notes any abnormalities during the dialysis session. Abnormalities on physical examination or problems with dialysis prompt a fistulogram. Similarly, an unexplained (&gt;0.2 units) persistent decrease in",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    prompts a fistulogram.",
"   </p>",
"   <p>",
"    In general, the role for surveillance of hemodialysis fistulas is unclear. In addition, the value of flow monitoring, the best technique, is currently debatable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/22/11619?source=see_link\">",
"       \"Patient information: Preparing for hemodialysis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surveillance of hemodialysis AV fistulas is performed by both clinical assessment and noninvasive methods to evaluate graft flow. Noninvasive assessment is preferred for efficient screening to identify those fistulas most likely to have stenosis. Those with sufficiently abnormal flow require a fistulogram and, if indicated, preemptive angioplasty. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prospective monitoring and surveillance for stenosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical monitoring falls into the following three broad categories: abnormalities of physical examination; problems noted during the dialysis session; and an unexplained decrease in the delivered dialysis dose",
"      <span class=\"nowrap\">",
"       (Kt/V)",
"      </span>",
"      on a constant hemodialysis prescription. Although not clearly reproducible, some experts suggest that failure of the fistula to collapse when the arm is elevated and the lack of pulse augmentation when the outflow vein is occluded transiently are particularly suggestive of underlying stenosis (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical monitoring'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The three major types of access surveillance are intra-access blood flow monitoring, static dialysis venous pressure, and duplex ultrasound. Flow monitoring is the optimal surveillance method for fistula stenosis, due most likely to the fistula being a low pressure system. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Surveillance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the lack of evidence suggesting efficacy with surveillance, the dialysis staff at our center performs physical examination of the fistula weekly, and notes any abnormalities during the dialysis session. Abnormalities on physical examination or problems with dialysis prompt a fistulogram. Similarly, an unexplained (&gt;0.2 units) persistent decrease in",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      prompts a fistulogram. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Our approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27429/abstract/1\">",
"      Turmel-Rodrigues L, Pengloan J, Rodrigue H, et al. Treatment of failed native arteriovenous fistulae for hemodialysis by interventional radiology. Kidney Int 2000; 57:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27429/abstract/2\">",
"      Allon M, Robbin ML. Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions. Kidney Int 2002; 62:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27429/abstract/3\">",
"      Maya ID, Oser R, Saddekni S, et al. Vascular access stenosis: comparison of arteriovenous grafts and fistulas. Am J Kidney Dis 2004; 44:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27429/abstract/4\">",
"      Asif A, Leon C, Orozco-Vargas LC, et al. Accuracy of physical examination in the detection of arteriovenous fistula stenosis. Clin J Am Soc Nephrol 2007; 2:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27429/abstract/5\">",
"      Polkinghorne KR, Lau KK, Saunder A, et al. Does monthly native arteriovenous fistula blood-flow surveillance detect significant stenosis--a randomized controlled trial. Nephrol Dial Transplant 2006; 21:2498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27429/abstract/6\">",
"      Schwarz C, Mitterbauer C, Boczula M, et al. Flow monitoring: performance characteristics of ultrasound dilution versus color Doppler ultrasound compared with fistulography. Am J Kidney Dis 2003; 42:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27429/abstract/7\">",
"      Tonelli M, Hirsch D, Clark TW, et al. Access flow monitoring of patients with native vessel arteriovenous fistulae and previous angioplasty. J Am Soc Nephrol 2002; 13:2969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27429/abstract/8\">",
"      Tessitore N, Bedogna V, Gammaro L, et al. Diagnostic accuracy of ultrasound dilution access blood flow measurement in detecting stenosis and predicting thrombosis in native forearm arteriovenous fistulae for hemodialysis. Am J Kidney Dis 2003; 42:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27429/abstract/9\">",
"      Besarab A, Sullivan KL, Ross RP, Moritz MJ. Utility of intra-access pressure monitoring in detecting and correcting venous outlet stenoses prior to thrombosis. Kidney Int 1995; 47:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27429/abstract/10\">",
"      K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations 2006 Updates Hemodialysis adequacy Peritoneal Dialysis Adequacy Vascular Access. Am J Kidney Dis 2006; 48(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27429/abstract/11\">",
"      McCarley P, Wingard RL, Shyr Y, et al. Vascular access blood flow monitoring reduces access morbidity and costs. Kidney Int 2001; 60:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27429/abstract/12\">",
"      Shahin H, Reddy G, Sharafuddin M, et al. Monthly access flow monitoring with increased prophylactic angioplasty did not improve fistula patency. Kidney Int 2005; 68:2352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27429/abstract/13\">",
"      Tessitore N, Mansueto G, Bedogna V, et al. A prospective controlled trial on effect of percutaneous transluminal angioplasty on functioning arteriovenous fistulae survival. J Am Soc Nephrol 2003; 14:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27429/abstract/14\">",
"      Tessitore N, Mansueto G, Lipari G, et al. Endovascular versus surgical preemptive repair of forearm arteriovenous fistula juxta-anastomotic stenosis: analysis of data collected prospectively from 1999 to 2004. Clin J Am Soc Nephrol 2006; 1:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27429/abstract/15\">",
"      Schwab SJ, Raymond JR, Saeed M, et al. Prevention of hemodialysis fistula thrombosis. Early detection of venous stenoses. Kidney Int 1989; 36:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27429/abstract/16\">",
"      Beathard GA. Percutaneous transvenous angioplasty in the treatment of vascular access stenosis. Kidney Int 1992; 42:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27429/abstract/17\">",
"      Windus DW, Audrain J, Vanderson R, et al. Optimization of high-efficiency hemodialysis by detection and correction of fistula dysfunction. Kidney Int 1990; 38:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27429/abstract/18\">",
"      Schwab SJ, Saeed M, Sussman SK, et al. Transluminal angioplasty of venous stenoses in polytetrafluoroethylene vascular access grafts. Kidney Int 1987; 32:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27429/abstract/19\">",
"      Collins DM, Lambert MB, Middleton JP, et al. Fistula dysfunction: effect on rapid hemodialysis. Kidney Int 1992; 41:1292.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1970 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-E01451B0F0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_50_27429=[""].join("\n");
var outline_f26_50_27429=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROSPECTIVE MONITORING AND SURVEILLANCE FOR STENOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      K/DOQI recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EFFECTIVENESS OF ACCESS SURVEILLANCE ON FISTULA THROMBOSIS AND ACCESS SURVIVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ROLE OF FISTULOGRAMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OUR APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23816?source=related_link\">",
"      Arteriovenous fistulas and grafts for chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/38/615?source=related_link\">",
"      Monitoring and surveillance of hemodialysis arteriovenous grafts to prevent thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/22/11619?source=related_link\">",
"      Patient information: Preparing for hemodialysis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_50_27430="Liver transplantation in primary biliary cirrhosis";
var content_f26_50_27430=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Liver transplantation in primary biliary cirrhosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/50/27430/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/50/27430/contributors\">",
"     Steven Flamm, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/50/27430/contributors\">",
"     Fredric D Gordon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/50/27430/contributors\">",
"     Raoul Poupon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/50/27430/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/50/27430/contributors\">",
"     Robert S Brown, Jr, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/50/27430/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/50/27430/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/50/27430/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver transplantation can be successful in treating end-stage liver disease from primary biliary cirrhosis (PBC). The total number of transplants performed for PBC in recent years has declined slightly, possibly reflecting benefits of early treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/1\">",
"     1",
"    </a>",
"    ]. Nevertheless, transplantation remains an important option in patients with progressive disease despite medical therapy. In the United States, the average age of patients undergoing transplantation for PBC is in the range of 53 to 55 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review issues related to patient selection for liver transplantation, the timing of transplantation, and transplantation outcomes in patients with PBC. Other issues related to the pathogenesis, clinical manifestations, diagnosis, and treatment of PBC are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/19/34105?source=see_link\">",
"     \"Overview of the treatment of primary biliary cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5737?source=see_link\">",
"     \"Pathogenesis of primary biliary cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43526?source=see_link\">",
"     \"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OPTIMAL TIME FOR TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important issue is to determine the optimal time to perform a liver transplantation. Many groups have developed models that use clinical variables to estimate patient survival. Two types of models have been developed: one based upon initial data on entry into the study, and one that uses both initial and follow-up data. The Mayo model (",
"    <a class=\"graphic graphic_table graphicRef65783 \" href=\"UTD.htm?43/20/44363\">",
"     table 1",
"    </a>",
"    ), which uses data from the initial evaluation, is most widely used, but because of individual patient variation, it does not replace the input of an experienced clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The Mayo model can predict short- and long-term survival using current laboratory and clinical data. This tool can be used to anticipate liver failure, allowing the clinician to refer the patient for transplantation in a timely manner. Although these models are specific to survival in PBC, transplantation in PBC is prioritized using the MELD score and is often used to determine when to refer patients for transplantation (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=see_link\">",
"     \"Model for End-stage Liver Disease (MELD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to considering the MELD score and Mayo model, we suggest that patients with PBC be referred for transplantation evaluation if one or more of the following is present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The plasma bilirubin concentration is greater than 5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      and is increasing",
"     </li>",
"     <li>",
"      The serum albumin concentration is below 2.8",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (28",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"      and is decreasing",
"     </li>",
"     <li>",
"      Signs of decompensation or portal hypertension develop, such as ascites, variceal bleeding, coagulopathy malnutrition, or encephalopathy",
"     </li>",
"     <li>",
"      The patient has intractable pruritus",
"     </li>",
"     <li>",
"      The patient has recurrent, debilitating, nontraumatic bone fractures",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Models based upon initial data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings on physical examination, laboratory data, and liver biopsy all have predictive value [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/2,4-7\">",
"     2,4-7",
"    </a>",
"    ]. Among the factors at entry into the study that have been found to correlate with prognosis are age, the plasma bilirubin and albumin concentrations, hepatomegaly, and the presence of cholestasis, portal fibrosis, or cirrhosis on biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A model developed at the Mayo Clinic does not require liver biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. Survival could be predicted from the patient's age, plasma bilirubin and albumin concentrations, the prothrombin time, and the presence of edema (",
"    <a class=\"graphic graphic_table graphicRef65783 \" href=\"UTD.htm?43/20/44363\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These models are all based upon data obtained at a fixed time point and do not consider more dynamic data such as changes over time or the response to therapy. Models that incorporate these elements would likely more accurately reflect disease progression in individual patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Models based upon initial and follow-up data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two time-dependent predictive models have been developed that use readily available markers and follow-up data to predict survival [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/8\">",
"     8",
"    </a>",
"    ]. These models therefore permit a change in the patient's condition to provide an updated prognosis. One uses the plasma albumin and bilirubin concentrations, the presence of ascites, a history of gastrointestinal bleeding, and age as important variables. The second uses the same variables and adds plasma immunoglobulin measurements and the presence of cirrhosis and central cholestasis on biopsy.",
"   </p>",
"   <p>",
"    Both models were validated and were more accurate than the time-fixed models in predicting survival, particularly in the short term. They suggest that liver transplantation be undertaken when the estimated six-month survival is less than 80 percent. Six months is used as the cut-off since this is the time when survival after transplantation becomes better than survival without transplantation (assuming that an organ is available for transplantation within six months) (",
"    <a class=\"graphic graphic_figure graphicRef62006 \" href=\"UTD.htm?36/33/37405\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OUTCOME AFTER LIVER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excellent short- and long-term survival have been repeatedly described following transplantation for PBC. An illustrative report that included 400 consecutive patients reported 1-, 5- and 10-year survival rates of 83, 78, and 67 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/9\">",
"     9",
"    </a>",
"    ]. One-year survival rates of 90 to 95 percent are now common at many medical centers.",
"   </p>",
"   <p>",
"    These results are significantly better than the predicted survival in nontransplanted patients derived from the models described above. A survival benefit has been demonstrated as early as three months after transplantation. As an example, one study monitored 161 patients with PBC after liver transplantation and compared the results to a simulated group of patients with the same diagnosis who were managed without transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/3\">",
"     3",
"    </a>",
"    ]. The three-month survival in this group was significantly higher than the predicted values in nontransplanted patients. The two-year survival was also higher with transplantation (74 versus 31 percent), a benefit that was seen in patients from all pretransplant risk groups (",
"    <a class=\"graphic graphic_figure graphicRef62006 \" href=\"UTD.htm?36/33/37405\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although all patients with PBC benefit from liver transplantation, those who are chronically ill and malnourished prior to surgery do not do as well as those with less severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/3\">",
"     3",
"    </a>",
"    ]. The Mayo model (",
"    <a class=\"graphic graphic_table graphicRef65783 \" href=\"UTD.htm?43/20/44363\">",
"     table 1",
"    </a>",
"    ) can help to identify high-risk patients. Unfortunately, the shortage of donor organs often limits transplantation to patients with advanced disease (and thus higher MELD scores), except for those with a suitable living donor. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Models based upon initial data'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=see_link\">",
"     \"Model for End-stage Liver Disease (MELD)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/4/25672?source=see_link\">",
"     \"Living donor liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with transplantation for other liver diseases, a very small proportion of patients with PBC require a second transplantation, less than 2 percent in our experience. While recurrent PBC is not uncommon, in one series of patients with recurrent PBC following liver transplantation, only 5 percent lost their grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/10\">",
"     10",
"    </a>",
"    ]. Most second transplants occur within the first month due to problems such as primary liver nonfunction, hepatic artery thrombosis, chronic rejection, acute rejection, and portal vein thrombosis, problems common to liver transplantation in general. This is an important issue because of the shortage in donor organs. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Rate of recurrence'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Effect of transplantation on symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resolution of symptoms related to PBC occurs at variable rates. Pruritus and complications of end-stage liver disease, such as encephalopathy, variceal bleeding, and hepatorenal syndrome are usually promptly reversed after transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23863?source=see_link\">",
"     \"Pruritus associated with cholestasis\"",
"    </a>",
"    .) Jaundice and ascites resolve somewhat more slowly, over a period of days to a few months. Splenomegaly usually persists, although the enlarged spleen may decrease slightly in size. Skin xanthomas also resolve within a few weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18149?source=see_link\">",
"     \"Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, it may take 12 to 18 months before improvement is seen in hepatic osteodystrophy, despite vitamin D and calcium supplementation. As a result, bone disease is a possible source of long-term morbidity (due to vertebral compression fractures, pain, opiate dependence, and immobility) despite successful liver transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29830?source=see_link\">",
"     \"Metabolic bone disease in primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Recurrence of PBC in the transplanted liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is now generally accepted that PBC can recur following liver transplantation, although there was much initial debate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/9,11-17\">",
"     9,11-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Rate of recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;A precise estimate of the recurrence rate is uncertain since not all studies have used uniform criteria for defining recurrent PBC, and studies have had variable follow-up. Two of the largest series with the longest follow-up (in which the diagnosis of recurrent PBC was based upon histologic features) probably represent the best available estimates [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/9,11\">",
"     9,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a report of 421 patients from Pittsburgh, PA, recurrent PBC was observed in 8 percent of patients after five years, and 22 percent after 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/11\">",
"     11",
"    </a>",
"    ]. Higher rates were described in a series of 400 patients from Birmingham, England, where recurrence was observed in 18 percent at five years and 30 percent at 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/9\">",
"     9",
"    </a>",
"    ]. A later report from the same group involving 485 patients found a recurrence rate of 23 percent during a median follow-up of 79 months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of recurrent PBC must be based upon histologic rather than serologic or biochemical findings. The following criteria have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transplantation for PBC,",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      Persistence of antimitochondrial antibodies,",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      Liver histology showing the characteristic portal tract lesions (mononuclear inflammatory infiltrate, formation of lymphoid aggregates, epithelioid granulomas, bile duct damage). Definite recurrent PBC is present when three of the four portal tract lesions are present, whereas probable recurrence is diagnosed when two are present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A cholestatic pattern of liver biochemical abnormalities is neither sensitive nor specific for recurrence. Cholestasis can arise from multiple causes in the transplant setting and not all patients with well documented histologic recurrence have cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/9,21\">",
"     9,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, the presence of antimitochondrial antibodies does not establish that recurrence is present or will develop. Antimitochondrial antibodies persist in most patients following transplantation, usually with a small and transient fall in their titer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for recurrence remain uncertain. However, the studies described above identified independent predictors including older recipient age, longer cold ischemia time, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ) and younger donor age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/9,11,18,24,25\">",
"     9,11,18,24,25",
"    </a>",
"    ]. The magnitude of risk associated with these variables remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Clinical significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical significance of recurrent disease is still being determined. Initial experience suggests that the rate of graft loss is very low, although graft failure from recurrent disease (and recurrence in the second graft) has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data to guide treatment of recurrent disease, although treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    (UDCA) is reasonable. UDCA appears to improve biochemical tests [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/20\">",
"     20",
"    </a>",
"    ], but its effect on the natural history of recurrent PBC is uncertain. UDCA was not associated with improved patient and graft survival compared with untreated patients in a retrospective study involving 52 patients with recurrent PBC [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/17\">",
"     17",
"    </a>",
"    ]. Some have found that the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    (0.6 mg twice daily) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodiol",
"    </a>",
"    in patients with recurrent PBC has resulted in improvements in serum enzyme and bilirubin levels and in liver histology [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27430/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/34/2594?source=see_link\">",
"       \"Patient information: Primary biliary cirrhosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liver transplantation in primary biliary cirrhosis (PBC) is prioritized using the Model for End-stage Liver Disease (MELD) score. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=see_link\">",
"       \"Model for End-stage Liver Disease (MELD)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In addition to considering the MELD score, we suggest that patients with PBC be referred for liver transplantation evaluation if one or more of the following is present (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Optimal time for transplantation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The plasma bilirubin concentration is greater than 5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      and is increasing",
"     </li>",
"     <li>",
"      The serum albumin concentration is below 2.8",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (28",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"      and is decreasing",
"     </li>",
"     <li>",
"      Signs of decompensation or portal hypertension develop, such as ascites, variceal bleeding, coagulopathy, malnutrition, or encephalopathy",
"     </li>",
"     <li>",
"      The patient has intractable pruritus",
"     </li>",
"     <li>",
"      The patient has recurrent, debilitating, nontraumatic bone fractures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Excellent short- and long-term survival have been repeatedly described following liver transplantation for PBC. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Outcome after liver transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Resolution of symptoms related to PBC occurs at variable rates following liver transplantation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Effect of transplantation on symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recurrent PBC after liver transplantation has been described in up to 30 percent of patients, depending upon the definition of recurrence and the length of follow-up. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Recurrence of PBC in the transplanted liver'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23618402\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's past work as an author for this topic, as well as his work as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/1\">",
"      Lee J, Belanger A, Doucette JT, et al. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007; 5:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/2\">",
"      Wiesner RH, Porayko MK, Dickson ER, et al. Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 1992; 16:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/3\">",
"      Markus BH, Dickson ER, Grambsch PM, et al. Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med 1989; 320:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/4\">",
"      Dickson ER, Grambsch PM, Fleming TR, et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/5\">",
"      Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 1983; 308:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/6\">",
"      Klion FM, Fabry TL, Palmer M, Schaffner F. Prediction of survival of patients with primary biliary cirrhosis. Examination of the Mayo Clinic model on a group of patients with known endpoint. Gastroenterology 1992; 102:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/7\">",
"      Goudie BM, Burt AD, Macfarlane GJ, et al. Risk factors and prognosis in primary biliary cirrhosis. Am J Gastroenterol 1989; 84:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/8\">",
"      Christensen E, Altman DG, Neuberger J, et al. Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. PBC1 and PBC2 trial groups. Gastroenterology 1993; 105:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/9\">",
"      Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001; 33:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/10\">",
"      Rowe IA, Webb K, Gunson BK, et al. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int 2008; 21:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/11\">",
"      Abu-Elamgd K, Demetris J, Rakela J, et al. Transplantation for primary biliary cirrhosis: Recurrence and outcome in 421 patients (abstract). Hepatology 1997; 26:176A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/12\">",
"      Polson RJ, Portmann B, Neuberger J, et al. Evidence for disease recurrence after liver transplantation for primary biliary cirrhosis. Clinical and histologic follow-up studies. Gastroenterology 1989; 97:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/13\">",
"      Balan V, Batts KP, Porayko MK, et al. Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation. Hepatology 1993; 18:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/14\">",
"      Esquivel CO, Van Thiel DH, Demetris AJ, et al. Transplantation for primary biliary cirrhosis. Gastroenterology 1988; 94:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/15\">",
"      Tzakis AG, Carcassonne C, Todo S, et al. Liver transplantation for primary biliary cirrhosis. Semin Liver Dis 1989; 9:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/16\">",
"      Haagsma EB, Manns M, Klein R, et al. Subtypes of antimitochondrial antibodies in primary biliary cirrhosis before and after orthotopic liver transplantation. Hepatology 1987; 7:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/17\">",
"      Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2007; 13:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/18\">",
"      Neuberger J, Gunson B, Hubscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2004; 10:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/19\">",
"      Hubscher SG, Elias E, Buckels JA, et al. Primary biliary cirrhosis. Histological evidence of disease recurrence after liver transplantation. J Hepatol 1993; 18:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/20\">",
"      Neuberger J. Recurrent primary biliary cirrhosis. Liver Transpl 2003; 9:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/21\">",
"      Slapak GI, Saxena R, Portmann B, et al. Graft and systemic disease in long-term survivors of liver transplantation. Hepatology 1997; 25:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/22\">",
"      Luettig B, Boeker KH, Schoessler W, et al. The antinuclear autoantibodies Sp100 and gp210 persist after orthotopic liver transplantation in patients with primary biliary cirrhosis. J Hepatol 1998; 28:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/23\">",
"      Dubel L, Farges O, Bismuth H, et al. Kinetics of anti-M2 antibodies after liver transplantation for primary biliary cirrhosis. J Hepatol 1995; 23:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/24\">",
"      Wong PY, Portmann B, O'Grady JG, et al. Recurrence of primary biliary cirrhosis after liver transplantation following FK506-based immunosuppression. J Hepatol 1993; 17:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27430/abstract/25\">",
"      Montano-Loza AJ, Wasilenko S, Bintner J, Mason AL. Cyclosporine A protects against primary biliary cirrhosis recurrence after liver transplantation. Am J Transplant 2010; 10:852.",
"     </a>",
"    </li>",
"    <li>",
"     Personal communication from Marshall Kaplan, MD. He observed that five of six patients treated with ursodeoxycholic acid and colchicine developed normal serum transaminase and bilirubin levels and became asymptomatic.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3609 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-6A12EA632A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_50_27430=[""].join("\n");
var outline_f26_50_27430=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OPTIMAL TIME FOR TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Models based upon initial data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Models based upon initial and follow-up data",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OUTCOME AFTER LIVER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Effect of transplantation on symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Recurrence of PBC in the transplanted liver",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Rate of recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Clinical significance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23618402\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3609\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3609|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/33/37405\" title=\"figure 1\">",
"      Survival after liver TPL in PBC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3609|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/20/44363\" title=\"table 1\">",
"      Need for liver TPL in PBC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=related_link\" title=\"calculator 1\">",
"      Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18149?source=related_link\">",
"      Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/4/25672?source=related_link\">",
"      Living donor liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29830?source=related_link\">",
"      Metabolic bone disease in primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/19/34105?source=related_link\">",
"      Overview of the treatment of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5737?source=related_link\">",
"      Pathogenesis of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/34/2594?source=related_link\">",
"      Patient information: Primary biliary cirrhosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23863?source=related_link\">",
"      Pruritus associated with cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43526?source=related_link\">",
"      Ursodeoxycholic acid in the treatment of primary biliary cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_50_27431="Chondroblastic osteosarcoma";
var content_f26_50_27431=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F87012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F87012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Chondroblastic osteosarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histologic appearance of a chondroblastic osteosarcoma with malignant chondrocytes and areas undergoing transformation to malignant osteoid with entrapped malignant cells (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of M John Hicks, DDS, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_50_27431=[""].join("\n");
var outline_f26_50_27431=null;
var title_f26_50_27432="Epidemiology of Neisseria meningitidis infection";
var content_f26_50_27432=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology of Neisseria meningitidis infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/50/27432/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/50/27432/contributors\">",
"     Michael Apicella, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/50/27432/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/50/27432/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/50/27432/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/50/27432/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/50/27432/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/50/27432/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningococcal disease, especially meningococcal meningitis, is one of the most devastating infections in an individual or community; reports of documented or suspected cases can engender considerable panic, even among well-informed hospital personnel. Part of the explanation for this phenomenon is the fact that meningitis due to Neisseria meningitidis tends to strike young, previously well individuals, and can progress over a matter of hours to death.",
"   </p>",
"   <p>",
"    Mortality can be very high if the infection is not treated appropriately, and long-term sequelae can be severe even in successfully managed cases. The mortality and morbidity from meningococcal disease has changed very little since the 1950s, principally due to the inability to effectively manage the endotoxin-induced vascular collapse frequently caused by this organism.",
"   </p>",
"   <p>",
"    N. meningitidis can cause both endemic and epidemic infection. Large numbers of individuals can become infected in a population within a short space of time. With the reduction in cases of meningitis due to Haemophilus influenzae, N. meningitidis has now become the second leading cause of meningitis in the United States. The majority of cases of meningococcal infection occur in young children and teenagers.",
"   </p>",
"   <p>",
"    This pathogen has the added capacity to cause epidemics in which all age groups in the entire population become at risk. While the worst of these epidemics have recently been largely confined to less-well developed areas of the world, epidemics have occurred in areas of Europe and North America where there are very high standards of living. Epidemic meningococcal infection can be a terrifying experience for the population affected. The progression of disease can be very rapid. The clinical features can be quite dramatic with profound shock, subcutaneous and gingival hemorrhage, thrombosis of vessels to extremities, delirium and coma leading to death within 24 hours.",
"   </p>",
"   <p>",
"    The epidemiology of infections due to N. meningitidis will be reviewed here. The microbiology, pathobiology, clinical features, diagnosis, treatment, and prevention of this infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7688?source=see_link\">",
"     \"Microbiology and pathobiology of Neisseria meningitidis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=see_link\">",
"     \"Clinical manifestations of meningococcal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27285?source=see_link\">",
"     \"Diagnosis of meningococcal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=see_link\">",
"     \"Treatment and prevention of meningococcal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link\">",
"     \"Meningococcal vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ATTACK RATES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningococcal infections are endemic in the United States, and the annual incidence of invasive meningococcal disease varies from 0.5 to 1.5 cases per 100,000 population in multiyear cycles; the most recent peak in incidence occurred during the mid 1990s (",
"    <a class=\"graphic graphic_figure graphicRef77474 \" href=\"UTD.htm?25/51/26429\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/1\">",
"     1",
"    </a>",
"    ]. In 2009, the rate of invasive meningococcal disease was 0.33 per 100,000 population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disease rates are almost 10 times higher in children below two years of age than in the overall population. The higher disease burden in children less than two years of age is illustrated by a multicenter surveillance study of invasive meningococcal infection in children that identified 159 cases between January 2001 and March 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/3\">",
"     3",
"    </a>",
"    ]. Twenty-six percent of cases occurred in children less than 12 months of age and 14 percent in children 12 to 24 months of age.",
"   </p>",
"   <p>",
"    In a second population-based survey of meningococcal disease conducted in the United States between 1992 and 1996, 39 percent of cases occurred in children below the age of two years, 17 percent in those under the age of one year [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/4\">",
"     4",
"    </a>",
"    ]. However, 32 percent of cases were detected in patients 30 years of age and older.",
"   </p>",
"   <p>",
"    Despite reports of outbreaks of cases on college campuses, a retrospective cohort study did not reveal an increase in the incidence of meningococcal infection in college students compared with age matched controls (1.74 versus 1.44 per 100,000 population) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/5\">",
"     5",
"    </a>",
"    ]. However, among affected college students, the rates of illness were higher for those residing on campus.",
"   </p>",
"   <p>",
"    Meningococcal infection displays seasonal variation in attack rates, which are highest in February and March and lowest in September. There is no predisposition by sex. The predominant serogroups causing infection in the United States currently are serogroups B, C, and Y.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H240598702\">",
"    <span class=\"h3\">",
"     Outbreak in New York City in men who have sex with men",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the fall of 2012, an outbreak of invasive serogroup C meningococcal disease was detected in men who have sex with men (MSM) in New York City [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Between 2010 and 2012, 18 cases were detected; 12 of which occurred in 2012. Ten of the 18 cases have been in HIV-infected men. As of late December 2012, five patients have died. For 2012, the incidence rate of invasive meningococcal disease among MSM aged 18 to 64 years in New York City was 12.6 per 100,000 persons, compared with 0.16 per 100,000 persons among non-MSM males of the same age. Vaccine recommendations for individuals at risk are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H21#H21\">",
"     \"Meningococcal vaccines\", section on 'In adults'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Outside the United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large scale epidemics still occur with deadly frequency in Africa, parts of Asia, South America, and the countries of the former Soviet Union. These epidemics are most commonly caused by N. meningitidis serogroup A and occasionally by serogroup C.",
"   </p>",
"   <p>",
"    Epidemics of meningococcal infection occur at irregular intervals, often every 7 to 10 years in the so-called \"meningitis belt\" of sub-Saharan Africa (",
"    <a class=\"graphic graphic_figure graphicRef63287 \" href=\"UTD.htm?16/45/17110\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The case rate during these epidemics can be as high as 1 in 1000 total population and 1 in 100 for children under two years of age.",
"   </p>",
"   <p>",
"    The World Health Organization (WHO) has endorsed a surveillance strategy to predict epidemics early and initiate vaccination drives. A study from Mali showed that detection of 5 cases per 100,000 population in one week was an appropriate threshold for alerting officials that vaccination might be required and 10 cases per 100,000 in one week confirmed regional epidemic activity with few false positive results [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/11\">",
"     11",
"    </a>",
"    ]. These numbers were in contrast to the WHO recommended threshold of 15 cases per 100,000 averaged over two weeks.",
"   </p>",
"   <p>",
"    In one epidemic in Nairobi, Kenya, which is outside of the meningitis belt, the attack rate was 2.5 cases per 10,000 population, with a case-fatality rate of approximately 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Areas that included Nairobi's largest slums were particularly affected. This epidemic displayed an unusual age distribution, with high attack rates among 20 to 29 year olds.",
"   </p>",
"   <p>",
"    W135 represents one of the more unusual serogroups of meningococci. The largest outbreak of infection due to this strain occurred among pilgrims returning in 2000 from the Hajj in Mecca, Saudi Arabia; 70 cases were reported to the World Health Organization (WHO) from Saudi Arabia, the United Kingdom, France, the Netherlands, and Oman [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/12\">",
"     12",
"    </a>",
"    ]. Three cases surfaced in the United States, one in a returning pilgrim and two in contacts of pilgrims [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Saudi Arabia requires meningococcal vaccination for all pilgrims based upon a 1987 outbreak of serogroup A meningococcal infection, but it is not clear that all travelers have access to the vaccine formulation containing W135. The CDC found that returning pilgrims from the 2001 Hajj had a higher likelihood of throat colonization with W135 than departing passengers in a pharyngeal carriage study, although only 27 total meningococcal isolates were recovered from 1320 individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The CDC continues to recommend that pilgrims receive quadrivalent meningococcal vaccine but not antibiotic prophylaxis upon their return based upon this study and several cases of invasive meningococcal infection reported in pilgrims returning to the United Kingdom who had received bivalent meningococcal vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/15\">",
"     15",
"    </a>",
"    ], although household contacts are at risk to develop the infection after contact with a pharyngeal carrier [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link\">",
"     \"Meningococcal vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serogroup W135 may also play a role in endemic infection. This was illustrated in a national surveillance study in South Africa in which the emergence of endemic serogroup W135 was associated with an increase in the incidence and severity of invasive meningococcal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/18\">",
"     18",
"    </a>",
"    ]. From 2000 through 2005, 2135 cases of invasive meningococcal disease were reported, 52 percent of which occurred in a single province. In this region, rates of disease increased from 0.8 cases per 100,000 persons in 2000 to 4.0 cases per 100,000 in 2005, and the proportion of cases due to serogroup W135 increased from 7 percent in 2000 to 75 percent in 2005. Overall case-fatality rates doubled from 11 percent in 2003 to 22 percent in 2005. Serogroup W135 was more likely to cause meningococcemia than serogroup A.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     GENETICS OF OUTBREAK STRAINS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a large population-based survey of meningococcal disease in the United States noted above, serogroups C, B, and Y accounted for 35, 32, and 26 percent of isolates, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/4\">",
"     4",
"    </a>",
"    ]. The proportion of cases caused by serogroup Y infection increased during the study period (11 percent in 1992 to 33 percent in 1996). Retrospective surveillance in Chicago also confirmed this trend [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/19\">",
"     19",
"    </a>",
"    ]. Twenty-five percent of 214 cases of meningococcal infection were serotype Y; the attack rate for this serotype increased from 0.04 per 100,000 in 1991 to 0.82 per 100,000 in 1995.",
"   </p>",
"   <p>",
"    Prior to World War II, periodic epidemics of meningococcal infection ravaged American cities, primarily caused by serogroup A. With increasing standards of living, these epidemics have abated in this country and infection due to this serogroup has virtually disappeared.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Outside the United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetics of the organisms causing epidemics in Africa have also been examined [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/20\">",
"     20",
"    </a>",
"    ]. Clone III-1 of N. meningitidis serogroup A has been traced to spread from the meningitis belt all the way to South Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/10,21\">",
"     10,21",
"    </a>",
"    ]. Techniques used to study these organisms include ribotyping, pulsed field gel electrophoresis, multilocus enzyme electrophoresis, and polymerase chain reaction (PCR).",
"   </p>",
"   <p>",
"    N.&nbsp;meningitidis can be organized into clonal complexes (CCs), which are groups of strains defined by multilocus sequence type analysis based on housekeeping genes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/22\">",
"     22",
"    </a>",
"    ].&nbsp;Sequence types (STs) that share a minimum of four identical alleles with a central (ancestral) ST are assigned to a CC; CCs are remarkably stable.&nbsp;Genomic analysis has demonstrated that the majority of cases of invasive meningococcal disease are caused by isolates that belong to a limited number of CCs, known as hyperinvasive lineages [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the developed nations of Western Europe, epidemics due to serogroup B meningococcus have occurred since the mid-1980s. Norway suffered such an epidemic with case rates of 1 in 10,000 individuals from 1985 to 1989. A high attack rate was seen among children as old as teenagers in this epidemic [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/25\">",
"     25",
"    </a>",
"    ]. In Belgium, 420 meningococcal isolates were characterized and compared to reference strains from the Netherlands and the rest of Europe, confirming the spread of epidemic N. meningitidis serogroup B from the Netherlands to Belgium [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outbreaks of a new serogroup C meningococcus causing disease emerged during 2003 to 2005 (10 outbreaks with 72 cases) in Anhui province, China [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/27\">",
"     27",
"    </a>",
"    ]. Molecular analysis established that the strain (sequence type-4821) did not belong to any of the previously reported sequence types, forming a new hypervirulent lineage; this strain should be monitored for future spread in China and the rest of the world.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR EPIDEMICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reason for the epidemic spread of the meningococcus is not known. The organism is considered a respiratory pathogen and spread is most likely by the aerosol route. It is clear that the high attack rates seen in the less well-developed countries are in part due to poverty and the consequences of crowding, poor sanitation, and malnutrition.",
"   </p>",
"   <p>",
"    Factors such as herd immunity and specific virulence properties associated with epidemic strains have been implicated as factors in the rapid spread of infection in these situations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/28\">",
"     28",
"    </a>",
"    ]. Clonal analysis of strains from one epidemic in central and east Africa indicated that the epidemic strain had arisen in central Asia almost seven years prior; spread occurred through Northern India and Pakistan to Saudi Arabia and then to Africa via pilgrims from Mecca [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/29\">",
"     29",
"    </a>",
"    ]. A number of American pilgrims returning from Mecca at that time were found to have nasopharyngeal colonization with this epidemic strain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR ACQUISITION OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of environmental and host factors have been associated with an increased risk for endemic acquisition of N. meningitidis infection. The major associated factor is nasopharyngeal carriage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nasopharyngeal carrier state",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of nasopharyngeal carriage of the meningococcus in the transmission of the organism and the development of disease was appreciated early based upon the experience with military recruits [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Epidemic infections in American military recruit camps were a major problem prior to the introduction of vaccination. Throughout the nineteenth century, the unique susceptibility of military recruits can be attested to by the clinical descriptions of this infection that can be found in the records of the Crimean and American Civil Wars. Since the introduction of vaccination of all recruits in the United States in 1972 with a tetravalent vaccine containing serogroup A, C, Y, and W135 polysaccharides, epidemics have not occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, vaccination of recruits is not universal around the world. The dynamics of carriage was studied in a 1998 report of military recruits in Denmark [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/34\">",
"     34",
"    </a>",
"    ]. The rate of carriage in 1069 recruits followed for three months during each of three separate seasons was 39 to 47 percent at entry and did not change appreciably with time or season. Both loss of carriage and acquisition was documented in individuals, with 34 percent experiencing one or more change in carrier status over time. No differences were observed in the acquisition of invasive strains, which had caused disease in other subjects, from other strains in this study.",
"   </p>",
"   <p>",
"    Another study examined the immune response in military recruits carrying the meningococcus or acquiring the organism in the pharynx during basic training [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/35\">",
"     35",
"    </a>",
"    ]. Increases in antibody to the colonizing strains were documented; individuals colonized with more than one strain made antibody responses only to the newly acquired strain. Serum bactericidal activity to the homologous strains was also demonstrated.",
"   </p>",
"   <p>",
"    Intimate contacts of cases, including family members, college roommates and nursery school classmates are at 100 to 1000 fold increased risk of acquiring meningococcal infection. In one study of contacts of patients with meningococcal infection from Norway, household and kissing contacts had an increased frequency of carriage of the pathogenic strain compared to less close contacts (12.4 versus 1.9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/36\">",
"     36",
"    </a>",
"    ]. Such individuals should be monitored closely for the development of co-primary cases (cases which arise within 48 hours of the primary case) and be given chemoprophylaxis to prevent secondary cases of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment and prevention of meningococcal infection\", section on 'Antimicrobial chemoprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of 2507 university students conducted in the United Kingdom, meningococcal carriage rates increased substantially during the fall term [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/38\">",
"     38",
"    </a>",
"    ]. During the first week of school (early October), the rate rose from 7 to 23 percent and the average rate for those living in dormitories increased from 14 percent at the beginning of October to 34 percent in December.",
"   </p>",
"   <p>",
"    When testing for nasopharyngeal carriage, cultures should be taken from the nasopharynx, since the rate of salivary carriage is very low (0.4 versus 35 percent in the nasopharynx or tonsils in a series of 258 college students) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to outbreaks and military recruits, N. meningitidis is occasionally identified on a throat culture. This issue is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment and prevention of meningococcal infection\", section on 'Nasopharyngeal carriage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Complement deficiency and meningococcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complement deficiency involving both the late and early components of the complement system have been associated with increased susceptibility to meningococcal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/40-49\">",
"     40-49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link\">",
"     \"Inherited disorders of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, the only known host defense defects associated with a terminal complement component deficiency are meningococcal disease and disseminated gonococcal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/40,48\">",
"     40,48",
"    </a>",
"    ]. Deficiencies of C3 and properdin are also associated with defective defense against Neisserial species, which is probably due to the key role of these components in efficiently activating C5 to C9 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/50\">",
"     50",
"    </a>",
"    ]. Meningococcal disease tends to present in patients with complement deficiencies later in life (late teens) than it does in normal individuals. These patients usually have a milder course; the mortality rate is lower (3 to 4 percent) compared with normal populations in the United States (6 to 12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An additional complement-related protein associated with meningococcal disease susceptibility is complement factor H (CFH), a regulator of complement activity. Two independent studies, one a case-control and the other a family based transmission-disequilibrium-test using United Kingdom patients identified that a polymorphism in the CFH gene was associated with an increased susceptibility to meningococcal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/51\">",
"     51",
"    </a>",
"    ]. In addition, a genome-wide association study showed that a cluster of complement factor single nucleotide polymorphisms (SNPs), including SNPs within genes regulating CFH and CFH-related protein 3, were present in individuals with meningococcal disease compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Meningococcemia due to the less common serotypes such as Y and W135, cause a proportionately higher percentage of infections in complement deficient populations. In a seminal study of 20 patients with first episodes of serious systemic meningococcal infection, six were demonstrated to have a complement deficiency, three in terminal complement protein(s) and three in multiple factors with accompanying underlying diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/45\">",
"     45",
"    </a>",
"    ]. If one considers patients who (1) have their first episode of Neisserial disease after age 10, or (2) are infected with an unusual serogroup of N. meningococci, or (3) suffer relapses or recurrences, then the likelihood of an underlying terminal complement deficiency or properdin deficiency is much higher [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A family with properdin deficiency has also been studied and found to have a high rate of fatal meningococcal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/43\">",
"     43",
"    </a>",
"    ]. A bactericidal defect was demonstrated to be correctable in these patients by vaccination. Use of the meningococcal tetravalent capsular polysaccharide conjugate vaccine in individuals deficient in late-complement components may focus host defense on phagocytosis rather than serum bactericidal activity, which is deficient in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other host factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other host factors have also been associated with increased susceptibility to meningococcal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/53\">",
"     53",
"    </a>",
"    ]. This issue was directly addressed in a matched cohort study of 114 adolescents (15 to 19 years of age) with meningococcal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/54\">",
"     54",
"    </a>",
"    ]. Significant independent risk factors for meningococcal disease were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of preceding illness (matched odds ratio [OR], 2.9; 95% CI, 1.4-5.9)",
"     </li>",
"     <li>",
"      Intimate kissing with multiple partners (matched OR, 3.7; 95% CI, 1.7-8.1)",
"     </li>",
"     <li>",
"      Being a university student (matched OR, 3.4; 95% CI, 1.2-10)",
"     </li>",
"     <li>",
"      Preterm birth (matched OR, 3.7; 95% CI, 1.0-13.5)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Factors associated with protection from disease were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Religious observance (matched OR, 0.09, 95% CI, 0.02-0.6)",
"     </li>",
"     <li>",
"      Meningococcal vaccination (matched OR, 0.12; 95% CI, 0.04-0.4)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Smoking appears to be another risk factor for meningococcal infection. In a study of 311 marine recruits, both active and passage cigarette smoking were implicated as risk factors for pharyngeal carriage of N. meningitidis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/55\">",
"     55",
"    </a>",
"    ]. In other studies, smoking has been associated with meningococcal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. In one report, having a mother who smokes was the strongest independent risk factor for invasive meningococcal disease in children less than 18 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With respect to passive smoking, it has been suggested that the increase in risk is more likely due to exposure to smokers, who are more likely to be carriers of N. meningitidis, than to exposure to smoke [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of other risk factors have been described. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attendance at a bar or disco [",
"      <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/57,59\">",
"       57,59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Preceding respiratory tract infection, particularly influenza virus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, a variety of genetic factors may affect susceptibility to meningococcal infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Variants in host alleles for mannose-binding lectin (MBL), a serum protein that activates the classical complement pathway and also serves as an opsonin, were associated with an increased susceptibility to meningococcal infection in a study comparing children with meningococcal infection to controls in two separate cohorts [",
"      <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/49\">",
"       49",
"      </a>",
"      ]. Homozygosity for variant MBL alleles was associated with a higher incidence of meningococcal infection (8 versus 2 percent in hospitalized patients and 8 versus 3 percent in a community population).",
"      <br/>",
"      <br/>",
"      The mechanism of such an effect remains uncertain. An in vitro study using serum from patients with terminal complement and MBL deficiency failed to demonstrate a significant role for MBL in opsonophagocytosis of meningococci [",
"      <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Single nucleotide polymorphisms (SNPs) in the human genes for surfactant proteins (SP-A1, SP-A2, and SP-D), proteins responsible for binding microorganisms such as N. meningitidis in the respiratory tract were analyzed in 303 patients with meningococcal disease and 22 healthy control subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/61\">",
"       61",
"      </a>",
"      ]. Homozygosity of allele 1A(1) of SP-A2 significantly increased the risk of meningococcal disease (odds ratio 7.4), while allele 1A(5) significantly reduced the risk (odds ratio 0.3). Genetic variations in SP-A1 and SP-D were not associated with meningococcal disease.",
"     </li>",
"     <li>",
"      Variations in the genes for interleukin (IL)-1 and its receptor did not influence susceptibility to meningococcal infection but did affect survival in a study from England and Wales [",
"      <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1413562701\">",
"    <span class=\"h2\">",
"     Occupational exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occupational acquisition of meningococcal disease has been described rarely in healthcare workers and first responders (eg, ambulance workers, police officers) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/62-64\">",
"     62-64",
"    </a>",
"    ], as well as in laboratory workers who handle N. meningitidis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study that assessed the risk of laboratory-acquired meningococcal disease by requesting information on email listserves of infectious disease, microbiology, and infection control professional organizations, 16 cases of probable laboratory-acquired meningococcal disease were identified worldwide between 1985 and 2001; half of the cases were fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27432/abstract/65\">",
"     65",
"    </a>",
"    ]. All cases occurred in clinical microbiologists, and in 15 of 16 cases (94 percent), N. meningitidis isolates were handled without respiratory protection. The estimated attack rate among microbiologists in the US between 1996 and 2001 was 13 per 100,000 microbiologists compared with 0.2 per 100,000 among the general adult US population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1413562504\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meningococcal disease, especially meningococcal meningitis, is one of the most devastating infections in an individual or community; reports of documented or suspected cases can engender considerable panic, even among well-informed hospital personnel. Part of the explanation for this phenomenon is the fact that meningitis due to Neisseria meningitidis tends to strike young, previously well individuals, and can progress over a matter of hours to death. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Meningococcal infections are endemic in the United States, and the annual incidence of invasive meningococcal disease varies from 0.5 to 1.5 cases per 100,000 population in multiyear cycles. The most recent peak in incidence occurred during the mid 1990s (",
"      <a class=\"graphic graphic_figure graphicRef77474 \" href=\"UTD.htm?25/51/26429\">",
"       figure 1",
"      </a>",
"      ). Disease rates are almost 10 times higher in children below two years of age than in the overall population. The predominant serogroups causing infection in the United States currently are serogroups B, C, and Y. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'United States'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Large scale epidemics still occur with deadly frequency in Africa, parts of Asia, South America, and the countries of the former Soviet Union. These epidemics are most commonly caused by N. meningitidis serogroup A and occasionally by serogroup C. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Outside the United States'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epidemics of meningococcal infection occur at irregular intervals, often every 7 to 10 years in the so-called \"meningitis belt\" of sub-Saharan Africa (",
"      <a class=\"graphic graphic_figure graphicRef63287 \" href=\"UTD.htm?16/45/17110\">",
"       figure 2",
"      </a>",
"      ). The case rate during these epidemics can be as high as 1 in 1000 total population and 1 in 100 for children under two years of age. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Outside the United States'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The reason for the epidemic spread of the meningococcus is not known. The organism is considered a respiratory pathogen and spread is most likely by the aerosol route. It is clear that the high attack rates seen in the less well-developed countries are in part due to poverty and the consequences of crowding, poor sanitation, and malnutrition. Factors such as herd immunity and specific virulence properties associated with epidemic strains have been implicated as factors in the rapid spread of infection in these situations. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Risk factors for epidemics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of environmental and host factors have been associated with an increased risk for endemic acquisition of N. meningitidis infection. The major associated factor is nasopharyngeal carriage. Complement deficiency involving both the late and early components of the complement system have also been associated with increased susceptibility to meningococcal infection. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Risk factors for acquisition of infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/1\">",
"      Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis 2010; 50 Suppl 2:S37.",
"     </a>",
"    </li>",
"    <li>",
"     US Centers for Disease Control and Prevention. Active Bacterial Core surveillance (ABCs) report: Neisseria meningitidis, 2009. file://www.cdc.gov/abcs/reports-findings/survreports/mening09.html (Accessed on April 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/3\">",
"      Kaplan SL, Schutze GE, Leake JA, et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics 2006; 118:e979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/4\">",
"      Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999; 180:1894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/5\">",
"      Harrison LH, Dwyer DM, Maples CT, Billmann L. Risk of meningococcal infection in college students. JAMA 1999; 281:1906.",
"     </a>",
"    </li>",
"    <li>",
"     New York State Department of Health. New York State Department of Health expands vaccination recommendation in response to meningococcal disease outbreak among high risk HIV positive men in New York City. file://www.health.ny.gov/press/releases/2012/2012-10-05_meningitis.htm (Accessed on October 26, 2012).",
"    </li>",
"    <li>",
"     Commonwealth of Masschusetts Department of Public Health. Health Advisory: Meningococcal vaccine recommendations for men who have sex with men. October 25, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: serogroup C invasive meningococcal disease among men who have sex with men - New York City, 2010-2012. MMWR Morb Mortal Wkly Rep 2013; 61:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/9\">",
"      Bhatt KM, Bhatt SM, Mirza NB. Meningococcal meningitis. East Afr Med J 1996; 73:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/10\">",
"      Hart CA, Cuevas LE. Meningococcal disease in Africa. Ann Trop Med Parasitol 1997; 91:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/11\">",
"      Lewis R, Nathan N, Diarra L, et al. Timely detection of meningococcal meningitis epidemics in Africa. Lancet 2001; 358:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/12\">",
"      Centers for Disease Control and Prevention (CDC). Serogroup W-135 meningococcal disease among travelers returning from Saudi Arabia--United States, 2000. MMWR Morb Mortal Wkly Rep 2000; 49:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/13\">",
"      Centers for Disease Control and Prevention (CDC). Update: assessment of risk for meningococcal disease associated with the Hajj 2001. MMWR Morb Mortal Wkly Rep 2001; 50:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/14\">",
"      Dull PM, Abdelwahab J, Sacchi CT, et al. Neisseria meningitidis serogroup W-135 carriage among US travelers to the 2001 Hajj. J Infect Dis 2005; 191:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/15\">",
"      Hahn&eacute; SJ, Gray SJ, Crowcroft NS, et al. W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001. Lancet 2002; 359:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/16\">",
"      Wilder-Smith A, Barkham TM, Ravindran S, et al. Persistence of W135 Neisseria meningitidis carriage in returning Hajj pilgrims: risk for early and late transmission to household contacts. Emerg Infect Dis 2003; 9:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/17\">",
"      Wilder-Smith A, Goh KT, Barkham T, Paton NI. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis 2003; 36:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/18\">",
"      von Gottberg A, du Plessis M, Cohen C, et al. Emergence of endemic serogroup W135 meningococcal disease associated with a high mortality rate in South Africa. Clin Infect Dis 2008; 46:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/19\">",
"      Racoosin JA, Whitney CG, Conover CS, Diaz PS. Serogroup Y meningococcal disease in Chicago, 1991-1997. JAMA 1998; 280:2094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/20\">",
"      Mueller JE, Sangar&eacute; L, Njanpop-Lafourcade BM, et al. Molecular characteristics and epidemiology of meningococcal carriage, Burkina Faso, 2003. Emerg Infect Dis 2007; 13:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/21\">",
"      McGee L, Koornhof HJ, Caugant DA. Epidemic spread of subgroup III of Neisseria meningitidis serogroup A to South Africa in 1996. Clin Infect Dis 1998; 27:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/22\">",
"      Maiden MC, Bygraves JA, Feil E, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 1998; 95:3140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/23\">",
"      Buckee CO, Jolley KA, Recker M, et al. Role of selection in the emergence of lineages and the evolution of virulence in Neisseria meningitidis. Proc Natl Acad Sci U S A 2008; 105:15082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/24\">",
"      Caugant DA, Maiden MC. Meningococcal carriage and disease--population biology and evolution. Vaccine 2009; 27 Suppl 2:B64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/25\">",
"      Hjetland R, Caugant DA, Hofstad T, et al. Serogroup A Neisseria meningitidis of clone III-1 present in western Norway as early as 1969-73. Scand J Infect Dis 1990; 22:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/26\">",
"      Van Looveren M, Vandamme P, Hauchecorne M, et al. Molecular epidemiology of recent belgian isolates of Neisseria meningitidis serogroup B. J Clin Microbiol 1998; 36:2828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/27\">",
"      Shao Z, Li W, Ren J, et al. Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, China. Lancet 2006; 367:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/28\">",
"      Morelli G, Malorny B, M&uuml;ller K, et al. Clonal descent and microevolution of Neisseria meningitidis during 30 years of epidemic spread. Mol Microbiol 1997; 25:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/29\">",
"      Denamur E, Pautard JC, Ducroix JP, et al. Meningococcal disease due to group A Neisseria meningitidis in contacts of Mecca pilgrims. Lancet 1987; 2:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/30\">",
"      Centers for Disease Control (CDC). Meningococcal disease among travelers returning from Saudi Arabia. MMWR Morb Mortal Wkly Rep 1987; 36:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/31\">",
"      Glover, JA. The cerebrospinal fever epidemic of 1917 at \"X\" depot. J R Army Med Corps 1918; 17:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/32\">",
"      Broome CV. The carrier state: Neisseria meningitidis. J Antimicrob Chemother 1986; 18 Suppl A:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/33\">",
"      Artenstein MS, Gold R, Zimmerly JG, et al. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med 1970; 282:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/34\">",
"      Andersen J, Berthelsen L, Bech Jensen B, Lind I. Dynamics of the meningococcal carrier state and characteristics of the carrier strains: a longitudinal study within three cohorts of military recruits. Epidemiol Infect 1998; 121:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/35\">",
"      Jones GR, Christodoulides M, Brooks JL, et al. Dynamics of carriage of Neisseria meningitidis in a group of military recruits: subtype stability and specificity of the immune response following colonization. J Infect Dis 1998; 178:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/36\">",
"      Kristiansen BE, Tveten Y, Jenkins A. Which contacts of patients with meningococcal disease carry the pathogenic strain of Neisseria meningitidis? A population based study. BMJ 1998; 317:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/37\">",
"      Purcell B, Samuelsson S, Hahn&eacute; SJ, et al. Effectiveness of antibiotics in preventing meningococcal disease after a case: systematic review. BMJ 2004; 328:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/38\">",
"      Neal KR, Nguyen-Van-Tam JS, Jeffrey N, et al. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study. BMJ 2000; 320:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/39\">",
"      Orr HJ, Gray SJ, Macdonald M, Stuart JM. Saliva and meningococcal transmission. Emerg Infect Dis 2003; 9:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/40\">",
"      Fijen CA, Kuijper EJ, te Bulte MT, et al. Assessment of complement deficiency in patients with meningococcal disease in The Netherlands. Clin Infect Dis 1999; 28:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/41\">",
"      Petersen BH, Graham JA, Brooks GF. Human deficiency of the eighth component of complement. The requirement of C8 for serum Neisseria gonorrhoeae bactericidal activity. J Clin Invest 1976; 57:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/42\">",
"      Alper CA, Abramson N, Johnston RB Jr, et al. Increased susceptibility to infection associated with abnormalities of complement-mediated functions and of the third component of complement (C3). N Engl J Med 1970; 282:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/43\">",
"      Densen P, Weiler JM, Griffiss JM, Hoffmann LG. Familial properdin deficiency and fatal meningococcemia. Correction of the bactericidal defect by vaccination. N Engl J Med 1987; 316:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/44\">",
"      Densen P. Complement deficiencies and meningococcal disease. Clin Exp Immunol 1991; 86 Suppl 1:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/45\">",
"      Ellison RT 3rd, Kohler PF, Curd JG, et al. Prevalence of congenital or acquired complement deficiency in patients with sporadic meningocococcal disease. N Engl J Med 1983; 308:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/46\">",
"      Ross SC, Rosenthal PJ, Berberich HM, Densen P. Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. J Infect Dis 1987; 155:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/47\">",
"      Read RC, Cannings C, Naylor SC, et al. Variation within genes encoding interleukin-1 and the interleukin-1 receptor antagonist influence the severity of meningococcal disease. Ann Intern Med 2003; 138:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/48\">",
"      Ross SC, Densen P. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Baltimore) 1984; 63:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/49\">",
"      Hibberd ML, Sumiya M, Summerfield JA, et al. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. Lancet 1999; 353:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/50\">",
"      Sj&ouml;holm AG. Inherited complement deficiency states: implications for immunity and immunological disease. APMIS 1990; 98:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/51\">",
"      Haralambous E, Dolly SO, Hibberd ML, et al. Factor H, a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients. Scand J Infect Dis 2006; 38:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/52\">",
"      Davila S, Wright VJ, Khor CC, et al. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat Genet 2010; 42:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/53\">",
"      Gardner P. Clinical practice. Prevention of meningococcal disease. N Engl J Med 2006; 355:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/54\">",
"      Tully J, Viner RM, Coen PG, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ 2006; 332:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/55\">",
"      Riordan T, Cartwright K, Andrews N, et al. Acquisition and carriage of meningococci in marine commando recruits. Epidemiol Infect 1998; 121:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/56\">",
"      Fischer M, Hedberg K, Cardosi P, et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J 1997; 16:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/57\">",
"      Imrey PB, Jackson LA, Ludwinski PH, et al. Outbreak of serogroup C meningococcal disease associated with campus bar patronage. Am J Epidemiol 1996; 143:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/58\">",
"      Coen PG, Tully J, Stuart JM, et al. Is it exposure to cigarette smoke or to smokers which increases the risk of meningococcal disease in teenagers? Int J Epidemiol 2006; 35:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/59\">",
"      Cookson ST, Corrales JL, Lotero JO, et al. Disco fever: epidemic meningococcal disease in northeastern Argentina associated with disco patronage. J Infect Dis 1998; 178:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/60\">",
"      Drogari-Apiranthitou M, Fijen CA, Thiel S, et al. The effect of mannan-binding lectin on opsonophagocytosis of Neisseria meningitidis. Immunopharmacology 1997; 38:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/61\">",
"      Jack DL, Cole J, Naylor SC, et al. Genetic polymorphism of the binding domain of surfactant protein-A2 increases susceptibility to meningococcal disease. Clin Infect Dis 2006; 43:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/62\">",
"      Gehanno JF, Kohen-Couderc L, Lemeland JF, Leroy J. Nosocomial meningococcemia in a physician. Infect Control Hosp Epidemiol 1999; 20:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/63\">",
"      Petsas A, Sharma A, Aghadiuno O, et al. A secondary case of meningococcal disease in an ambulance worker, Berkshire, November 2007. Euro Surveill 2008; 13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/64\">",
"      Centers for Disease Control and Prevention (CDC). Occupational transmission of Neisseria meningitidis --- California, 2009. MMWR Morb Mortal Wkly Rep 2010; 59:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27432/abstract/65\">",
"      Sejvar JJ, Johnson D, Popovic T, et al. Assessing the risk of laboratory-acquired meningococcal disease. J Clin Microbiol 2005; 43:4811.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1298 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-6EBEB1F6CE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_50_27432=[""].join("\n");
var outline_f26_50_27432=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1413562504\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ATTACK RATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      United States",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H240598702\">",
"      - Outbreak in New York City in men who have sex with men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Outside the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GENETICS OF OUTBREAK STRAINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      United States",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Outside the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RISK FACTORS FOR EPIDEMICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RISK FACTORS FOR ACQUISITION OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nasopharyngeal carrier state",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Complement deficiency and meningococcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other host factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1413562701\">",
"      Occupational exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1413562504\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1298\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1298|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/51/26429\" title=\"figure 1\">",
"      US meningococcal disease incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/45/17110\" title=\"figure 2\">",
"      Meningitis belt map",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=related_link\">",
"      Clinical manifestations of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27285?source=related_link\">",
"      Diagnosis of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=related_link\">",
"      Inherited disorders of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7688?source=related_link\">",
"      Microbiology and pathobiology of Neisseria meningitidis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=related_link\">",
"      Treatment and prevention of meningococcal infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_50_27433="Sagittal view female pelvis";
var content_f26_50_27433=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 628px\">",
"   <div class=\"ttl\">",
"    Sagittal view of female pelvis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 608px; height: 417px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal view of the female pelvis. The peritoneal sac drapes over the ovary, reproductive organs, and rectum. The thick body of the uterus transitions to the vagina through a cervix. An archway, or fornix, at the upper end of the vaginal canal surrounds the cervix and brushes into contact with the peritoneum posteriorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Baltimore 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_50_27433=[""].join("\n");
var outline_f26_50_27433=null;
var title_f26_50_27434="Parenteral nutrition in premature infants";
var content_f26_50_27434=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Parenteral nutrition in premature infants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/50/27434/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/50/27434/contributors\">",
"     Richard J Schanler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/50/27434/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/50/27434/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/50/27434/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/50/27434/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/50/27434/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nutritional needs of premature infants are usually dependent upon parenteral nutrition (PN) during early postnatal life, especially for very low birth weight (VLBW) infants (birth weight of less than 1500 g). In these infants, full enteral feedings are generally delayed because of the severity of medical problems associated with prematurity, such as immature lung function (which often requires endotracheal intubation and mechanical ventilation), hypothermia, infections, and hypotension. In addition, early enteral feeds are also delayed because of concerns that aggressive feeding may lead to complications, such as feeding intolerance or necrotizing enterocolitis. As a result, the nutritional requirements of VLBW infants are rarely met by enteral feeds in the first two weeks after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31992?source=see_link\">",
"     \"Short-term complications of the premature infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PN (sometimes referred to as hyperalimentation) in the premature infant, including its composition, will be reviewed here. The approach to enteral nutrition in premature infants is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/8/19593?source=see_link\">",
"     \"Approach to enteral nutrition in the premature infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GOALS OF PARENTERAL NUTRITION (PN)",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is growing evidence that inadequate nutrition in the first weeks of life of premature infants results in growth failure that is often difficult to correct and may lead to permanent detrimental effects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23912?source=see_link\">",
"     \"Growth management in preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The early use of adequate PN minimizes weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/5\">",
"     5",
"    </a>",
"    ], improves growth and neurodevelopmental outcome, and appears to reduce the risk of mortality and later adverse outcomes, such as necrotizing enterocolitis and bronchopulmonary dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Increased protein and energy intakes in the first week of life also are associated with improved neurodevelopmental outcome. In one study of 148 extremely low birth weight (ELBW) survivors (birth weight below 1000 g), increasing caloric and protein intakes during the first week of life were associated with increases in the Bayley Mental Development Index (MDI) scores at 18 months of corrected age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants born at the beginning of the third trimester of pregnancy often are growth-restricted because of decreased intrauterine nutrient deposition [",
"      <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Medical conditions including hypotension, hypoxia, acidosis, hypothermia, infection, and recovery from surgical procedures increase metabolic energy requirements and thus nutrient needs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because adequate enteral nutrition cannot be established in most very low birth weight (VLWB) infants in their early weeks, PN is initiated to correct in-utero growth restriction and to prevent subsequent growth failure.",
"   </p>",
"   <p>",
"    PN for the premature infant includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adequate calories for energy expenditure and growth",
"     </li>",
"     <li>",
"      Carbohydrates to prevent hypoglycemia and, in combination with lipids, to provide the caloric intake to meet the energy needs of the infant",
"     </li>",
"     <li>",
"      Adequate protein intake, including essential amino acids, to achieve positive nitrogen balance required for growth",
"     </li>",
"     <li>",
"      Fatty acids to prevent essential fatty acid deficiency and maximize overall nonprotein energy intake",
"     </li>",
"     <li>",
"      Essential nutrients including minerals (ie, calcium magnesium, and phosphorus), electrolytes, vitamins, and trace elements (eg, copper, zinc, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      ), which are needed for growth",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The recommended nutrient needs for medically stable and growing premature infants receiving either parenteral or enteral nutrition are shown in the linked table (",
"    <a class=\"graphic graphic_table graphicRef75039 \" href=\"UTD.htm?41/46/42733\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ENERGY NEEDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In premature infants, energy requirements must cover both energy needed for energy expenditure (resting metabolic rate, activity, and thermoregulation) and for growth [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The premature infant has an energy requirement of 80 to 100",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day by the end of the first week when nourished parenterally, which is generally lower than the energy requirement needed with enteral nutrition. This lower energy requirement is due to less fecal energy loss (energy excreted), and usually lower energy needs for activity and thermoregulation because of their controlled thermoneutral environment. Initially, caloric intake of 30 to 40",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day is given to prevent catabolism, and is advanced to the full energy needs of the infant.",
"   </p>",
"   <p>",
"    Carbohydrates and fat primarily provide the calories for energy. Protein intake, including essential amino acids, should be sufficient to attain positive nitrogen balance by covering the needs generated by protein turnover (protein catabolism) and tissue growth. The distribution of nonprotein calories derived from carbohydrates and lipids is similar to that of human milk, which is generally about 40 and 45 percent of calories from fat and carbohydrates, respectively.",
"   </p>",
"   <p>",
"    Studies have shown that mixtures that favor a higher distribution of glucose (ie, carbohydrates) may result in adverse effects on respiratory metabolism. Surplus calories from glucose result in glucose conversion to fat, which increases the production of carbon dioxide and raises the partial pressure of carbon dioxide (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ) leading to an increased minute ventilation and respiratory quotient, and a possible rise in oxygen consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In addition, a balanced distribution of calories from glucose and fat favors protein accretion, while intake of glucose-only parenteral nutrition (PN) (ie, without lipids) is associated with protein oxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monitoring of the intakes for all energy sources is essential to ensure that a balanced distribution of calories is derived from glucose and fat. In our institution parenteral nutrition (PN) is calculated to provide about 55, 30, and 15 percent of calories as carbohydrates, lipids, and amino acids, respectively (",
"    <a class=\"graphic graphic_table graphicRef64194 \" href=\"UTD.htm?24/43/25275\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GLUCOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose is the source of carbohydrate used in parenteral nutrition (PN). In the premature infant, glucose regulation may be challenging with the patient at risk for hypo- and hyperglycemic episodes.",
"   </p>",
"   <p>",
"    Soon after birth, exogenous glucose is often needed until the infant can begin to mobilize glycogen stores and produce glucose. High glucose infusion rates (approximately 5 to 8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute) may be required in the preterm infant to prevent hypoglycemia because of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucose is the primary energy substrate for the brain, which makes up a greater proportion of body weight in preterm infants compared with term infants and older children. This results in a higher glucose need in premature infants.",
"     </li>",
"     <li>",
"      Decreased fat stores reduces gluconeogenesis.",
"     </li>",
"     <li>",
"      Higher energy expenditure due to complications of prematurity such as respiratory distress and hypothermia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31992?source=see_link\">",
"       \"Short-term complications of the premature infant\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the definition of neonatal hypoglycemia remains controversial, we evaluate and treat newborns with a plasma glucose concentration less than 45",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in the first 24 hours after birth and afterwards; many clinicians use a threshold concentration of less than 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.8",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=see_link&amp;anchor=H2#H2\">",
"     \"Neonatal hypoglycemia\", section on 'Definition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=see_link&amp;anchor=H20#H20\">",
"     \"Neonatal hypoglycemia\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants with extremely low birth weights (ELBW) (birth weights less than 1000 g) are particularly susceptible to hyperglycemia, particularly in the first few days of life. The proposed reasons for this complication include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ineffective insulin secretion",
"     </li>",
"     <li>",
"      End-organ insulin resistance",
"     </li>",
"     <li>",
"      Decreased glucose intracellular transporters",
"     </li>",
"     <li>",
"      Elevated catecholamines and glucocorticoids, which alter glucose metabolism by stimulating glucose production and limiting glucose utilization",
"     </li>",
"     <li>",
"      Absence of enteral nutrition, which stimulates insulin secretion",
"     </li>",
"     <li>",
"      Provision of high glucose intakes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Insulin therapy has been proposed to treat hyperglycemia in these patients, but no threshold glucose concentration has been adopted. Neonatal hyperglycemia and its management, including insulin therapy, are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37816?source=see_link\">",
"     \"Neonatal hyperglycemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The early initiation of amino acid and lipid infusion in ELBW infants is another alternate strategy to prevent hyperglycemia, as they contribute substrates for gluconeogenesis, allowing for lower glucose infusion rates, thereby reducing the potential risk of hyperglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Early administration'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In our practice, for the ELBW infant, we start a glucose infusion rate at 3.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute and advance the rate daily, or as tolerated, by 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute to a maximum of 12",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute. No glucose infusion rate greater than 12",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute is needed unless there are underlying conditions, such as hyperinsulinemia (",
"    <a class=\"graphic graphic_table graphicRef67634 \" href=\"UTD.htm?16/45/17116\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If an ELBW infant develops hyperglycemia, and glucose infusion rates have been minimized (by using only 5 percent glucose), then insulin therapy often is provided. High insulin infusion rates should make one suspicious that the infant may be severely limited in",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    ability to utilize glucose, such as the case following a severe intraventricular hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     AMINO ACIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The delivery of adequate intakes of both protein and energy, and an optimal mixture of",
"    <span class=\"nowrap\">",
"     essential/nonessential",
"    </span>",
"    amino acids is required to achieve a positive nitrogen balance, which results in protein accruement and growth [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. With no amino acid intake, very low birth weight (VLBW) infants lose the equivalent of 0.5 to 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day of protein due to protein catabolism in the first days after birth. The combined use of early amino acids and glucose infusion within their first 24 hours replaces urinary protein loss due to protein breakdown (",
"    <a class=\"graphic graphic_table graphicRef67634 \" href=\"UTD.htm?16/45/17116\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Early administration'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In premature infants receiving parenteral nutrition (PN), an amino acid intake of 3.5 to 4",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day is needed to meet the intrauterine accretion rate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. One review of the literature suggested that intakes of &ge;4",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day were tolerated without adverse effects and were associated with lower rates of bronchopulmonary dysplasia when compared with intakes of 3",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For a fixed nitrogen intake, nitrogen retention increases with increasing energy intake from 50 to 90",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/16,22\">",
"     16,22",
"    </a>",
"    ]. As a result, one needs to consider both nitrogen and energy intake in order to optimize a positive nitrogen balance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The essential amino acids in PN include isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine. In the premature infant, other amino acids may be conditionally essential because the premature infant has a limited ability to synthesize them. They include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/32/27138?source=see_link\">",
"     cysteine",
"    </a>",
"    , glutamine, glycine, histidine, taurine, and tyrosine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ideal mixture of amino acids for PN in premature infants is unknown. Amino acid solutions have been designed to meet the protein requirements of premature infants based upon the composition of breast milk. These solutions, when compared with standard amino acid formulations originally designed for adults, result in a more balanced plasma amino acid pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/18,23-25\">",
"     18,23-25",
"    </a>",
"    ], and increased weight gain and net nitrogen retention [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The different amino acid preparations available for PN administration in premature infants vary in their concentration of protein (from 40 to 53 percent) and their composition of specific amino acids. For example, tyrosine and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/32/27138?source=see_link\">",
"     cysteine",
"    </a>",
"    are not present in all preparations because of difficulties in solubility [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/18,26,27\">",
"     18,26,27",
"    </a>",
"    ]. Taurine and glutamic acid are also not present in all solutions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/18,28\">",
"     18,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Cysteine and glutamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been proposed that supplementation of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/32/27138?source=see_link\">",
"     cysteine",
"    </a>",
"    and glutamine will improve patient outcome.",
"   </p>",
"   <p>",
"    One possible mechanism is that supplementation of these two amino acids improves glutathione synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Glutathione is a major intracellular antioxidant and its primary function is to protect cells from free-radical damage (eg, peroxides). The liver synthesizes glutathione from cysteine, glutamine, and glycine. However, in a trial that randomly assigned standard (45",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) and high dose of cysteine (81",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day), there were no differences in glutathione concentration and synthesis, or in the plasma levels of cystine between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In two reviews of the literature, glutamine did not add any important clinical benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first review, supplementation of glutamine to standard parenteral nutrition did",
"      <strong>",
"       not",
"      </strong>",
"      improve protein retention or weight gain, and did not reduce the risk of mortality or late-onset sepsis in extremely low birth weight (ELBW) infants [",
"      <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a subsequent review, supplementation of parenteral glutamine did",
"      <strong>",
"       not",
"      </strong>",
"      affect mortality, incidence of invasive infection or necrotizing enterocolitis, weight gain, time to full enteral nutrition, or length of hospital stay [",
"      <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent trial of 52 preterm infants reported that glutamine supplementation was associated with increased magnetic resonance imaging (MRI) white matter, hippocampal and brain stem volume at school age, and also with a lower risk of serious neonatal infections during the first months of life [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/34\">",
"     34",
"    </a>",
"    ]. However, the number of patients in this trial was small and 42 percent of patients were lost at the time of follow-up (ie, eight and nine years of age).",
"   </p>",
"   <p>",
"    In a meta-analysis, the supplementation of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/32/27138?source=see_link\">",
"     cysteine",
"    </a>",
"    (as HCI) was associated with an improved nitrogen balance, but did not significantly affect growth [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/35\">",
"     35",
"    </a>",
"    ]. Cysteine lowers the pH of the mixture, which serves to augment the solubility of calcium and phosphorus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/36\">",
"     36",
"    </a>",
"    ]. Occasionally, the use of cysteine hydrochloride results in a mild metabolic acidosis, so the addition of acetate may be required [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/19,37\">",
"     19,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further research is needed to determine whether there is any clinical benefit from the supplementation of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/32/27138?source=see_link\">",
"     cysteine",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    glutamine to PN in preterm infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Early administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned previously, the early administration of amino acids with glucose within the first 24 hours after birth reverses the protein loss of 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day due to catabolism and is well tolerated without serious adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/19,38-40\">",
"     19,38-40",
"    </a>",
"    ]. This intervention also increases the serum concentration of all amino acids, including essential amino acids [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/38,41,42\">",
"     38,41,42",
"    </a>",
"    ], and the rate of protein synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/39,43,44\">",
"     39,43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommended regimen is to start immediately after birth with an amino acid infusion rate of 3",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day. This regimen is associated with improved nitrogen balance without affecting serum blood urea nitrogen (BUN) or glucose concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study in ELBW infants demonstrated that the early use of amino acids and lipids resulted in lower glucose infusion rate, which may reduce the incidence of hyperglycemia, a common problem in premature infants [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/15\">",
"     15",
"    </a>",
"    ]. These results demonstrated that gluconeogenesis occurs in very premature infants. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Glucose'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37816?source=see_link\">",
"     \"Neonatal hyperglycemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term data regarding the effect of early administration of high amino acid intake (&gt;2.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day) on neurodevelopmental and growth outcomes are limited. In one study of ELBW infants, mean weight, length, and head circumference at 36 weeks postmenstrual age were greater in infants who received an amino acid intake of 3",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day by five days of age compared with those with lower intakes of amino acids, but only increased improved head circumference in male patients was observed at 18 months corrected age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/47\">",
"     47",
"    </a>",
"    ]. There was no difference in neurodevelopmental outcome at 18 months corrected age between the two groups.",
"   </p>",
"   <p>",
"    In another small prospective study, the administration of amino acids before 24 hours of life in VLBW infants resulted in greater weight gain at the time of discharge than a historical control group who received amino acids after 24 hours of life, after adjusting for gestational age and time from birth to discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/48\">",
"     48",
"    </a>",
"    ]. In addition, the early-administered amino acid group also had a shorter duration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our practice, we deliver an amino acid intake of 3",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    on the day of birth or as soon as is practical thereafter, and advance this intake by the end of the first week to 4",
"    <span class=\"nowrap\">",
"     g/kg/day",
"    </span>",
"    as fluid intakes increase.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/32/27138?source=see_link\">",
"     Cysteine",
"    </a>",
"    hydrochloride supplementation (30",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    amino acids) is added to the PN at approximately three days of age. We do not currently add glutamine as a supplement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LIPIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous lipid administration provides essential fatty acids (ie, linoleic and linolenic acids) that cannot be synthesized by humans, and is an important nonprotein source of energy. Small amounts of essential fatty acids (approximately 4 percent of caloric intake or 0.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day) are required to prevent essential fatty acid deficiency. Without supplementation, clinical manifestations of fatty acid deficiency (such as dermatitis, thrombocytopenia, and increased likelihood of infection and failure to thrive) become apparent by the end of the first week after birth.",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/9/19606?source=see_link\">",
"     fat emulsion",
"    </a>",
"    (IL) formulations used in premature infants contain varying combinations of soybean, safflower, or fish oils, with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/10/26787?source=see_link\">",
"     glycerin",
"    </a>",
"    and egg yolk phospholipids added as emulsifiers (",
"    <a class=\"graphic graphic_table graphicRef74733 \" href=\"UTD.htm?15/27/15805\">",
"     table 4",
"    </a>",
"    ). When given as early as parenteral nutrition (PN), intravenous lipid prevents essential fatty acid deficiency, provides needed energy for tissue healing and growth, and balances the distribution of nonprotein calories (",
"    <a class=\"graphic graphic_table graphicRef64194 \" href=\"UTD.htm?24/43/25275\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67634 \" href=\"UTD.htm?16/45/17116\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IL has been given to premature infants who have been severely ill on the first day of life without short-term adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/51\">",
"     51",
"    </a>",
"    ]. In one review, there were no differences in growth, the risk of lung disease, and overall morbidity and mortality between early (defined as &le;5 days after birth) and late use of IL [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     10 versus 20 percent IL",
"    </span>",
"    &nbsp;&mdash;&nbsp;IL is available in the United States as two different concentrations, 10 and 20 percent solutions. A 30 percent emulsion has not been investigated in premature infants. In premature infants, at similar or even greater doses of IL, the 20 percent IL solution appears to be better tolerated because the 10 percent solution requires a larger administered volume and is associated with a poorer clearance of triglycerides due to interference from lipoprotein X [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/18,53,54\">",
"     18,53,54",
"    </a>",
"    ]. The accumulation of lipoprotein X appears to be due to the higher ratio of phospholipids to triglycerides in the 10 percent solution [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/18,53,54\">",
"     18,53,54",
"    </a>",
"    ]. As a result, at the same dose of lipid, infants who receive 20 percent IL solution compared with those who receive 10 percent solution better tolerate and utilize the infused lipids, as demonstrated by their lower serum concentrations of triglyceride, cholesterol, and phospholipid [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. In our institution, we use the 20 percent IL solution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Continuous versus intermittent infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;IL can be infused either continuously or intermittently. In the premature infant, intermittent infusion (administered over less than 24 hours) appears to produce higher and more variable serum triglyceride concentrations than continuous infusion (over a 24 hour interval) if both are given at the same lipid dose [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/55\">",
"     55",
"    </a>",
"    ]. There are data in adults that suggest large bolus dosing of IL results in markedly elevated serum triglyceride concentrations (&gt;300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [4",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    that may have deleterious effects on pulmonary function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/56\">",
"     56",
"    </a>",
"    ]. Similar observations are reported in premature infants receiving large bolus doses of IL [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/57\">",
"     57",
"    </a>",
"    ]. As a result, we advocate the use of continuous infusion during routine IL administration over 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/55,58,59\">",
"     55,58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because triglyceride concentrations will be highest in the first week after birth for any given lipid dose [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/57\">",
"     57",
"    </a>",
"    ], we initiate IL as a continuous infusion of 20 percent IL at a dose of 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day and advance as tolerated to a target of 3",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day. A dose of 4",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day occasionally is used in a chronically ill infant unable to tolerate enteral feedings to meet",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    energy needs.",
"   </p>",
"   <p>",
"    Most neonatologists monitor serum triglyceride to measure IL tolerability with a target value of less than 150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Although measurement of plasma or serum free fatty acid provides a more direct measure of lipid tolerance, this assay is complicated to perform and is not routinely available.",
"   </p>",
"   <p>",
"    It appears that higher initial lipid dosing in the first week of life, which would improve energy intake, may be tolerable in the very low birth weight (VLBW) infant without an increase in significant adverse events. This was illustrated. in a trial of 110 VLBW infants who were randomly selected to receive either an initial high dose of lipid of 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    or a control dose of 0.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    lipid [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/60\">",
"     60",
"    </a>",
"    ]. In both groups, lipid dosing was increased 0.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day as tolerated to a maximum intake of 3.5",
"    <span class=\"nowrap\">",
"     g/kg.",
"    </span>",
"    The higher lipid dose group compared with controls had a higher energy intake in the first week of life and achieved an energy goal of 90",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day sooner (mean of 7.4 versus 9.4 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/60\">",
"     60",
"    </a>",
"    ]. The higher lipid dose group was more likely to have hypertriglyceridemia (defined as &gt;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.3",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    than the control group (15 versus 4 percent). There was no increase in adverse events in the higher lipid dose group.",
"   </p>",
"   <p>",
"    Although these results are encouraging, further trials with larger number of patients that show the tolerability of high dose lipid infusion in the first week of life without an increase in adverse events are needed before an initial dose greater than 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    can be universally recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;IL complications in the neonate include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of hyperlipidemia and hypertriglyceridemia increase with decreasing gestational age and sepsis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/61\">",
"       61",
"      </a>",
"      ]. A short-term decrease in the lipid infusion rate is usually sufficient to normalize serum lipid levels with a goal of maintaining serum triglyceride below 150",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.3",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Although there is no direct evidence that IL increases indirect hyperbilirubinemia, there is a theoretical concern that fatty acids may displace bilirubin from albumin-binding sites, leading to an increase in free serum bilirubin [",
"      <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/62\">",
"       62",
"      </a>",
"      ]. As a result, IL rates are limited to less than 3",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day in cases of extreme hyperbilirubinemia (eg, approaching exchange level transfusion) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/63\">",
"       63",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link\">",
"       \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some studies have shown that IL may interfere with pulmonary oxygenation by altering pulmonary vascular tone and pulmonary artery pressure through thromboxane-mediated pathways or by the formation of free radicals (eg, hydroperoxides) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/64-66\">",
"       64-66",
"      </a>",
"      ]. However, other studies have shown that the use of IL, even when administered within the 12 hours of birth, was not associated with impairment of pulmonary function [",
"      <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/52,67\">",
"       52,67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the current available data, the benefits of IL, providing a nonprotein energy source and preventing fatty acid deficiency, outweigh the potential adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     New lipid formulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A newer IL formulation (Omegaven) utilizes fish oil, which contains long-chain polyunsaturated fatty acids (eg, docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA]) (",
"    <a class=\"graphic graphic_table graphicRef74733 \" href=\"UTD.htm?15/27/15805\">",
"     table 4",
"    </a>",
"    ). This formulation was designed to replace the plant fatty acids (eg, plant phytosterols) derived from soybean lipid emulsions, which have been thought to be proinflammatory and contribute to liver damage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/68\">",
"     68",
"    </a>",
"    ]. In one study of infants with short bowel syndrome, reversal of cholestasis due to prolonged PN exposure was quicker in 18 infants who received Omegaven compared with 21 historical controls who received soybean emulsions (9.4 versus 44 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/69\">",
"     69",
"    </a>",
"    ]. In addition, the Omegaven group compared with the soybean emulsion group had fewer deaths (two versus seven) and liver transplantations (zero versus two). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18730?source=see_link&amp;anchor=H22#H22\">",
"     \"Parenteral nutrition-associated liver disease in infants\", section on 'Fish oil-based fat emulsions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, randomized controlled trials are needed to determine whether this formulation is more beneficial than the standard IL formulations used in premature infants. This formulation is not available for routine use in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OTHER NUTRIENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Calcium, phosphorus, and magnesium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premature infants are prone to the following abnormalities in mineral metabolism, which may affect the mineral content of parenteral nutrition (PN).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypocalcemia &ndash; The premature infant may have inadequate calcium (Ca) reserves because most of the maternal to fetal transfer of calcium occurs in the last trimester of pregnancy. After birth, serum calcium generally declines because of reduced calcium intake, possible impaired response to parathyroid hormone, increased calcitonin levels, and increased urinary loss. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/23/26999?source=see_link&amp;anchor=H6#H6\">",
"       \"Neonatal hypocalcemia\", section on 'Prematurity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Phosphate metabolic abnormalities &ndash; In premature infants, serum phosphorus (P) is often elevated after delivery because glomerular filtration rate (GFR) is low resulting in a decreased phosphorus excretion. As GFR improves and the infant moves from a catabolic to anabolic state with cellular phosphorus uptake, phosphorus supplementation will be required. Without adequate phosphorus, hypophosphatemia results in impaired bone deposition and hypercalcemia.",
"     </li>",
"     <li>",
"      Hypermagnesemia may occur in premature infants whose mothers were treated with magnesium (Mg) therapy. However, once serum magnesium normalizes, magnesium supplementation is required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In premature infants, inadequate intakes of calcium and phosphorus result in bone undermineralization. Clinical manifestations depend upon the degree of impaired bone mineralization and may include osteopenia of prematurity, rickets, and fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. Bone undermineralization may affect chest wall stability leading to atelectasis and an increased risk of chronic lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the net retention is dependent upon the intake of these minerals, the intakes are limited by the solubility of Ca and P in PN solution. Because Ca and P solubility are affected by pH, amino acid concentration and source (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/32/27138?source=see_link\">",
"     cysteine",
"    </a>",
"    increases Ca and P solubility), and temperature of the PN solution, adjustment of these factors can increase Ca and P solubility and intake [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. To optimize solubility during PN preparation, P is added first and Ca is added as the last step.",
"   </p>",
"   <p>",
"    Although higher daily intakes can be achieved by separate delivery of Ca and P [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/75\">",
"     75",
"    </a>",
"    ], alternate-day infusion methods result in hypercalciuria and hypercalcemia on the days when P is omitted, and hyperphosphaturia and hyperphosphatemia when Ca is omitted. As a result, the two minerals should not be administered separately, but rather together to optimize bone deposition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Recommended intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proportional increases in elemental Ca and P, up to 80",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of Ca, result in increased net retention of minerals in premature infants [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/74,76\">",
"     74,76",
"    </a>",
"    ]. In one study, net retention of both minerals rose with increasing elemental Ca intakes from 60 to 80",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day and P from 55 to 80",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day resulting in higher bone mineral content during and after the PN study period [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The amount of Ca and P supplementation is dependent upon whether the infant is term or preterm, the anticipated length of parenteral nutrition, age of the infant (early, less than five days of age, and late, greater than five days of age), and the quantity of amino acid in the solution (",
"    <a class=\"graphic graphic_table graphicRef52282 \" href=\"UTD.htm?37/28/38347\">",
"     table 5",
"    </a>",
"    ). Immediately after birth, PN should include enough Ca to prevent and treat early hypocalcemia associated with prematurity.",
"   </p>",
"   <p>",
"    In general, the dose of elemental Ca ranges from 25 to 75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/77\">",
"     77",
"    </a>",
"    ]. Phosphorus may not be needed in the first one or two days (",
"    <a class=\"graphic graphic_table graphicRef67634 \" href=\"UTD.htm?16/45/17116\">",
"     table 3",
"    </a>",
"    ), but should be added when serum P stabilizes (",
"    <a class=\"graphic graphic_table graphicRef52282 \" href=\"UTD.htm?37/28/38347\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The optimal ratio of Ca to P in PN is generally between 1:1.3 and 1:1.7 by weight and nearly a 1:1 molar ratio. Lower ratios result in elevated urinary and serum P suggesting inadequate utilization of P because of insufficient Ca intake [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Vitamins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamins are a number of chemically unrelated families of organic substances that cannot be synthesized by humans. They are divided into water-soluble and fat-soluble vitamins.",
"   </p>",
"   <p>",
"    Premature infants need higher amounts of some vitamins than do term infants because of increased requirements for growth",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    greater losses. However, there are no products that are designed to specifically meet the needs of premature infants. Pediatric vitamin formulations that are currently used do not provide sufficient quantities of all vitamins to maintain the recommended normal vitamin concentrations in premature infants (",
"    <a class=\"graphic graphic_table graphicRef76606 \" href=\"UTD.htm?12/22/12653\">",
"     table 6",
"    </a>",
"    ). In particular, the multivitamin formulations provide insufficient amounts of vitamin A and, perhaps, excessive amounts of ascorbic acid (vitamin C) and riboflavin (vitamin B2). Until a vitamin solution is developed specifically for premature infants, we continue to use a modified amount of the pediatric preparation starting from the day of birth. Using this regimen, generally physiologic levels of vitamin A and E can be achieved in the preterm infant (",
"    <a class=\"graphic graphic_table graphicRef76606 \" href=\"UTD.htm?12/22/12653\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Vitamin A",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin A is a fat-soluble vitamin with multiple functions including effects on vision (corneal and conjunctival development, and phototransduction), immunocompetency, and cell differentiation. The biochemistry, metabolism, and actions of vitamin A are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21736?source=see_link\">",
"     \"Overview of vitamin A\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In premature infants, vitamin A is necessary for normal lung growth and maintaining the integrity of respiratory tract epithelial cells. A meta-analysis that included eight trials of 653 very low birth weight (VLBW) infants (birth weight &lt;1500 g) demonstrated that supplementation of vitamin A (administrated either enterally or parenterally), compared with no supplementation, reduced the risk of death or oxygen requirement at one month of age (RR 0.93, 95% CI 0.88-0.99), and oxygen requirement among survivors at 36 weeks postmenstrual age (RR 0.87, 95% CI 0.77-0.98) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/78\">",
"     78",
"    </a>",
"    ]. In three of the trials, a trend towards a reduction in retinopathy of prematurity (ROP) was also noted (RR 0.44, 95% CI 0.68-1.06). The vitamin A supplementation studies were conducted in populations where the rate of chronic lung disease was high (approximately 55 to 60 percent). In these studies, vitamin A was administered intramuscularly three times per week for a month. Thus, the benefits of therapy must be balanced with the risks and discomfort of injections, and the overall current incidence of chronic lung disease in a particular neonatal intensive care unit (NICU).",
"   </p>",
"   <p>",
"    VLBW infants have lower levels of vitamin A: one-third have hepatic vitamin stores &lt;20",
"    <span class=\"nowrap\">",
"     g/g",
"    </span>",
"    (indicative of deficiency) and three-fourths have stores of &lt;40",
"    <span class=\"nowrap\">",
"     g/g",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/79\">",
"     79",
"    </a>",
"    ]. However, vitamin A is the most difficult vitamin to provide parenterally in sufficient quantities to VLBW infants without administering excessive quantities of other vitamins because of its loss through photodegradation and binding to the PN-containing bag and tubing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Greater plasma concentrations occur when the vitamin is mixed with intravenous lipid emulsion or with the use of retinyl esters [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/82,83\">",
"     82,83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Vitamin E",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin E is a free-radical scavenger (antioxidant) that protects polyunsaturated fatty acids (PUFA), a major structural component of the cell membranes, from peroxidation. Data from older randomized trials in premature infants suggested that vitamin E reduced the risk of bronchopulmonary dysplasia (BPD) and ROP. However, subsequent studies have demonstrated either no or a very modest risk reduction with the use of pharmacologic doses of vitamin E [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/84-91\">",
"     84-91",
"    </a>",
"    ]. Older studies, which have not been repeated, also suggested that administration of vitamin E within 12 hours of birth reduced the incidence and severity of intraventricular hemorrhage (IVH) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. The suggested target plasma level of &gt;1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    by 24 hours of life and &gt;2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    at three days of age for reducing IVH [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/94\">",
"     94",
"    </a>",
"    ] is achieved with administration of the recommended dose of the currently available multivitamin formulations, which provide a vitamin E dose of 2.8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, soon after birth (",
"    <a class=\"graphic graphic_table graphicRef76606 \" href=\"UTD.htm?12/22/12653\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Water-soluble vitamins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The currently available multivitamin formulations generally provide more water-soluble vitamins than are needed by premature infants. The current dosing of pediatric multivitamin formulations (eg, 40 percent of the MVI-Pediatric vial) results in no demonstrated deficiencies in thiamine (vitamin B1), riboflavin (vitamin B2), folate, and vitamin 12 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/95\">",
"     95",
"    </a>",
"    ]. There are several reports of elevated levels of plasma ascorbic acid (vitamin C), and riboflavin (vitamin B2) in premature infants receiving PN [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/82,96,97\">",
"     82,96,97",
"    </a>",
"    ], but it is unclear whether or not these increased concentrations have any adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Electrolytes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Sodium and potassium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum sodium (Na) is a useful indication of the hydration status of premature infants in the first few days after birth. Na and potassium (K) supplementation is not generally required in the early, immediate PN for premature infants because infants are normally born with excessive extracellular fluid and there is a normally a sodium diuresis that occurs in the first 24 to 48 hours.",
"   </p>",
"   <p>",
"    After the first 24 hours after birth, serum Na and K concentrations are monitored and supplementation is adjusted on a daily basis. In general, maintenance requirements for a growing premature infant are about 2 to 4",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    for both Na and K. However, other sources of parenteral sodium intake, such as intravenous saline infusions or flushes used to administer medications, need to be considered when calculating the sodium requirements for PN [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/98\">",
"     98",
"    </a>",
"    ]. Usually Na supplementation is commenced when physiologic weight loss has been achieved, and the serum Na concentration is starting to decline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Acetate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In premature infants who receive PN, metabolic acidosis may commonly occur because of their decreased renal reabsorption of bicarbonate, and because the PN solution, which contains amino acids (especially with the addition of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/32/27138?source=see_link\">",
"     cysteine",
"    </a>",
"    hydrochloride), is usually acidic with a pH that ranges from 5.5 to 6.5 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/18\">",
"     18",
"    </a>",
"    ]. The addition of acetate (1 to 2",
"    <span class=\"nowrap\">",
"     mEq/kg",
"    </span>",
"    per day) as either a Na or K salt corrects and prevents the acidosis. This small quantity of acetate does not appear to affect the solubility of minerals in PN solutions that contain amino acids and cysteine hydrochloride [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Trace elements",
"    </span>",
"    &nbsp;&mdash;&nbsp;In-utero accretion of trace elements primarily takes place in the final trimester of pregnancy. As a result, premature infants are at risk for deficiency of these nutrients because of their low body stores and increased requirements for growth.",
"   </p>",
"   <p>",
"    Calculated daily intake needs for the following trace elements are based upon the birth weight and intrauterine accretion rate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/99,100\">",
"     99,100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Birth weight &le;2.5 kg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Zinc: 400",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"     </li>",
"     <li>",
"      Copper: 20",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"     </li>",
"     <li>",
"      Chromium: 0.4",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"     </li>",
"     <li>",
"      Manganese: 1",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       Selenium",
"      </a>",
"      : 2",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Birth weight &gt;2.5 kg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Zinc: 250",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"     </li>",
"     <li>",
"      Copper: 10",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"     </li>",
"     <li>",
"      Chromium: 0.1",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"     </li>",
"     <li>",
"      Manganese: 2.5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       Selenium",
"      </a>",
"      : 1.5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The only trace elements recommended from the first day PN are zinc and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/99,101\">",
"     99,101",
"    </a>",
"    ]. The other trace elements are not needed until after two weeks of age. Iron, another trace element, is not needed in the first few weeks after birth and is not routinely added to PN.",
"   </p>",
"   <p>",
"    Larger amounts of zinc may be needed in infants with intestinal losses, such as diarrhea, or intestinal surgery or disease (eg, necrotizing enterocolitis) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29753?source=see_link&amp;anchor=H9#H9\">",
"     \"Zinc deficiency and supplementation in children and adolescents\", section on 'Other'",
"    </a>",
"    ). Because copper and manganese are excreted in the bile, the intake of these elements should be reduced in patients with impaired bile excretion, which occurs in cholestatic syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/99\">",
"     99",
"    </a>",
"    ]. In these patients, we reduce the frequency of copper and manganese administration to twice a week. Selenium is renally excreted and its intake should be reduced in patients with impaired renal function.",
"   </p>",
"   <p>",
"    Pediatric trace metal solutions commonly added to PN contain zinc, copper, manganese, and chromium.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     Selenium",
"    </a>",
"    , a component of glutathione peroxidase, must be added as a supplement [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/102-104\">",
"     102-104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Carnitine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     Carnitine",
"    </a>",
"    , an important nutrient, is an intermediary in fat metabolism. It is required to shuttle long-chain fatty acids, such as acylcarnitine, into mitochondria for beta-oxidation. Carnitine is, therefore, crucial for energy production in tissues dependent upon fatty acid oxidation, such as cardiac and skeletal muscle. It is present in human milk and formula but is not included in the standard PN formulations.",
"   </p>",
"   <p>",
"    In premature infants, supplementation with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     L-carnitine",
"    </a>",
"    (8 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) increases serum total and acylcarnitine concentrations in premature infants compared with no supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. Infants who received",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     carnitine",
"    </a>",
"    appeared to have a greater rate of fatty acid oxidation as evidenced by increased ketone production [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/106\">",
"     106",
"    </a>",
"    ]. Supplementation with high doses of carnitine (48",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day), however, results in a slower weight gain and an anomalous increase in protein oxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/67\">",
"     67",
"    </a>",
"    ]. Carnitine supplementation, in general, is not associated with improvements in weight gain or with a reduction in apnea episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/107,108\">",
"     107,108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Premature infants are at increased risk for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency due to their limited reserves and insufficient rates of synthesis. In preterm infants who require prolonged PN of more than two weeks duration, we administer parenteral carnitine intakes in doses of 10 to 20",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    until adequate enteral nutrition is established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following sections discuss issues regarding the administration of parenteral nutrition (PN), which include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Route of administration",
"     </li>",
"     <li>",
"      Content of PN based upon the timing of administration",
"     </li>",
"     <li>",
"      Monitoring",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Route",
"    </span>",
"    &nbsp;&mdash;&nbsp;PN can be infused through peripheral or central veins (usually the superior or inferior vena cava). In most cases, PN will be infused through a central line.",
"   </p>",
"   <p>",
"    Line infection is the most serious complication of PN. If possible, the continuity of PN infusion should not be interrupted to reduce the risk of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Timing and contents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In extremely low birth weight (ELBW) infants, PN should be administered within the first day of life to provide adequate nutrition to minimize early weight loss and protein breakdown, and improve growth outcome. Balancing the distribution of calories between nonprotein sources (ie, lipids and carbohydrates) and protein sources is critical to optimize protein accretion and avoid adverse effects upon respiratory metabolism and protein oxidation (",
"    <a class=\"graphic graphic_table graphicRef64194 \" href=\"UTD.htm?24/43/25275\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Energy needs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In our institution, the contents of early PN (on the day of birth or soon thereafter) include the following (",
"    <a class=\"graphic graphic_table graphicRef67634 \" href=\"UTD.htm?16/45/17116\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/109\">",
"     109",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucose starting at 3.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per minute (5",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      day) and slowly increasing to 12",
"      <span class=\"nowrap\">",
"       mg/kg/min",
"      </span>",
"      over several days. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Glucose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Amino acids at 3.5",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day with increasing increments as tolerated to 4",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Amino acids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lipids at 1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day with increasing increments as tolerated to 3",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Lipids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electrolytes are not initially included in early PN, but are added as needed based upon laboratory evaluation. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Electrolytes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31\">",
"       'Monitoring'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Other nutrients &ndash; Calcium (650",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) and multivitamins.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients who require ongoing administration of PN, caloric concentration is increased to provide adequate calories for growth. In addition, trace elements, phosphorus, magnesium, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/32/27138?source=see_link\">",
"     cysteine",
"    </a>",
"    are added to PN for optimal growth. A general protocol for the routine administration of PN in premature infants is shown in the linked table (",
"    <a class=\"graphic graphic_table graphicRef81451 \" href=\"UTD.htm?11/54/12141\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/99,109\">",
"     99,109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the recommendation of providing parenteral nutrition in the first few days of life, it is a challenge to ensure that each infant receives the full complement of nutrients. This was illustrated in a multicenter study of 1187 extremely premature infants (gestational age below 28 weeks) in whom the administration of nutrients did not fully meet the established guidelines for the participating centers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/110\">",
"     110",
"    </a>",
"    ]. In this study, the protein, fat, and energy recommended goals for the first day of life were not met. By days four and six of life, the protein (3.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day) and fat (3.1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day) intakes achieved recommended levels, respectively, but energy (26 to105",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day) and glucose intake remained suboptimal through day 28 of life. Although the administrated PN did not meet the centers' guidelines, the median growth velocity (GV) exceeded the currently accepted rate of 15",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day. However, 75 percent of the infants were below the 10",
"    <sup>",
"     th",
"    </sup>",
"    percentile for weight by day 28. Patients in the lowest GV quartile also were in the lowest quartiles of protein, carbohydrate, and fat intake on day seven of life.",
"   </p>",
"   <p>",
"    These findings emphasize the importance of early nutrition on GV. The results also demonstrate that the generally acceptable GV rate of 15",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    does not maintain the fetal growth rate at the same gestational age (ie, intrauterine growth rate). The study does emphasize the difficulty of meeting projected nutrient intakes and opens the door for significant research in this area including determining the energy intake for optimal growth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory monitoring is required to adjust the contents of PN to avoid excesses or deficiencies of any given nutrient and to monitor for PN-associated complications, such as cholestasis and metabolic bone disease. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following laboratory tests should be obtained in any infant who is receiving PN. The frequency of the lab testing is found in the linked table (",
"    <a class=\"graphic graphic_table graphicRef56456 \" href=\"UTD.htm?14/27/14779\">",
"     table 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urine glucose &ndash; Glycosuria indicates hyperglycemia with elevated serum glucose exceeding the renal resorptive threshold resulting in urinary spillage.",
"     </li>",
"     <li>",
"      Serum triglycerides &ndash; Measurement of serum triglycerides is commonly used to adjust intravenous lipid dosing. Although consensus does not exist on what is the appropriate threshold of serum triglycerides, some clinicians use an arbitrary value between 150 and 200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.7 and 2.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      to determine whether to advance or reduce intravenous lipid infusion rates. In our practice, we generally maintain triglyceride values below 150",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.7",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Blood urea nitrogen (BUN) &ndash; An elevated BUN is a nonspecific marker for a problem with amino acid administration, and may be indicative of inadequate amino acid or energy intake, or excessive amino acid intake [",
"      <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/111\">",
"       111",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum electrolytes including sodium (Na), potassium (K), chloride (Cl), and bicarbonate (CO",
"      <sub>",
"       2",
"      </sub>",
"      ) are monitored and the PN is readjusted based upon their values.",
"     </li>",
"     <li>",
"      Calcium (Ca), phosphorus (P), and magnesium (Mg) are also adjusted based upon their monitoring.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Although uncommon, hypocalcemia usually signifies inadequate Ca intake. Hypercalcemia is more common and may be a manifestation of inadequate P intake. Once additional P is added, elevated serum Ca levels normalize.",
"     </li>",
"     <li>",
"      Serum P is a good monitor of P intake",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      renal function. A low P indicates that more P should be added to PN.",
"     </li>",
"     <li>",
"      In infants whose mother received Mg therapy, serum magnesium will be initially elevated and decline over the first week after birth. When serum Mg returns to normal levels, Mg can be added to PN.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alkaline phosphatase participates in the mineralization of bone and growth plate cartilage. An elevated level is a marker of bone mobilization as either rapid growth with copious mineral deposition or as occasionally seen PN, bone mobilization due to inadequate intakes of Ca and P. The role of serum alkaline phosphatase in monitoring bone mineral metabolism is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40567?source=see_link\">",
"       \"Calcium and phosphorus requirements of newborn infants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Liver function tests including serum conjugated bilirubin and aminotransferases (ie, ALT and AST) are markers for hepatic dysfunction and cholestasis.",
"     </li>",
"     <li>",
"      Creatinine elevation indicates renal dysfunction. If present, nutrients that are renally excreted may need to be readjusted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring and adjusting the parenteral nutrition (PN) contents can avoid many of the reported PN-associated complications in premature infants, such as electrolytes, glucose, calcium (Ca), and phosphorus (P) abnormalities. However, the following significant complications due to PN still may occur in premature infants:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cholestasis &ndash; Cholestasis is a serious complication of PN and is manifested by jaundice due to a direct hyperbilirubinemia. This complication is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18730?source=see_link\">",
"       \"Parenteral nutrition-associated liver disease in infants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infection and sepsis &ndash; Line infection is a common complication of PN in premature infants. The two most common bacterial agents are Staphylococcus epidermidis and Staphylococcus aureus [",
"      <a class=\"abstract\" href=\"UTD.htm?26/50/27434/abstract/112\">",
"       112",
"      </a>",
"      ]. In the extremely low birth weight (ELBW) infants, candidal infections have increased in frequency and are associated with the administration of PN and the use of central venous catheters. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24039?source=see_link&amp;anchor=H8#H8\">",
"       \"Epidemiology and risk factors for Candida infection in neonates\", section on 'Risk factors for invasive candidiasis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other line complications include infiltration and potentially skin sloughing, and air embolus.",
"     </li>",
"     <li>",
"      Bone disease may occur if adequate nutrients are not provided. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Calcium, phosphorus, and magnesium'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/23/26999?source=see_link\">",
"       \"Neonatal hypocalcemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the first weeks after birth before adequate enteral nutrition can be established, parenteral nutrition (PN) is initiated to help treat in-utero growth restriction and to lessen postnatal growth failure in very low birth weight premature infants (birth weight less than 1500 g).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The components of PN provide the following (",
"    <a class=\"graphic graphic_table graphicRef75039 \" href=\"UTD.htm?41/46/42733\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76606 \" href=\"UTD.htm?12/22/12653\">",
"     table 6",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Energy needs &ndash; PN should provide sufficient calories for energy expenditure (resting, metabolic rate, activity, and thermoregulation) and growth. The premature infant who receives parenteral nutrition has an energy need of 80 to 100",
"      <span class=\"nowrap\">",
"       kcal/kg",
"      </span>",
"      per day by the end of the first week. Initially, caloric intake of 30 to 40",
"      <span class=\"nowrap\">",
"       kcal/kg",
"      </span>",
"      per day is given to prevent catabolism, and is advanced to the full energy needs. Carbohydrates and fat primarily provide the calories for energy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Energy needs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Carbohydrates &ndash; Glucose is the carbohydrate used in PN and is a major source of caloric intake needed to meet energy needs. Exogenous glucose is needed after delivery to prevent hypoglycemia. In our practice, we start a glucose infusion rate at 3.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per minute and advance the rate daily, as tolerated, by 1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per minute to a maximum of 12",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per minute. Serum glucose should be monitored because premature infants, especially extremely low birth weight (ELBW) infants (birth weights &lt;1000 g ), are susceptible to both hypo- and hyperglycemia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Glucose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Amino acids &ndash; The delivery of adequate intakes of both protein and energy, and an optimal mixture of",
"      <span class=\"nowrap\">",
"       essential/nonessential",
"      </span>",
"      amino acids are needed to achieve a positive nitrogen balance required for growth and to prevent protein turnover. Early administration of amino acids within the first 24 hours of life prevents protein breakdown and is well tolerated. In our practice, we start an amino acid infusion rate at 3.5",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day with increasing increments as tolerated to 4",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Amino acids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lipids &ndash; Intravenous lipid (IL) administration provides essential fatty acids (ie, linoleic and linolenic acids) that cannot be synthesized by humans and is an important nonprotein source of energy (",
"      <a class=\"graphic graphic_table graphicRef74733 \" href=\"UTD.htm?15/27/15805\">",
"       table 4",
"      </a>",
"      ). We initiate IL infusion as a continuous infusion using a 20 percent solution at a dose of 1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day and advance as tolerated to a target of 3",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day. A dose of 4",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day occasionally is used in a chronically ill infant unable to tolerate enteral feedings. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Lipids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that early PN be given on the first day of life. It should include glucose (5 percent), amino acids (3.5",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day), calcium (650",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or 3",
"      <span class=\"nowrap\">",
"       mEq/dL",
"      </span>",
"      or 1.5",
"      <span class=\"nowrap\">",
"       mmol/dL),",
"      </span>",
"      multivitamins, zinc, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef67634 \" href=\"UTD.htm?16/45/17116\">",
"       table 3",
"      </a>",
"      ). In a separate access site, IL at 1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day is infused. Total fluids are restricted to 100",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per day in the first week.",
"     </li>",
"     <li>",
"      Other nutrients &ndash; Other nutrients are included once \"usual PN\" is initiated:",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"       carnitine",
"      </a>",
"      , minerals (magnesium, and phosphorus), vitamins, electrolytes (sodium, potassium, chloride, and acetate), and trace elements (copper, zinc, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      ) required for growth. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Other nutrients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Administration and complications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PN can be infused through peripheral or central veins. However, in most cases, PN is administered through a central line. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Route'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In ELBW infants, PN should be administered within the first day after birth to provide adequate nutrition to minimize early weight loss and protein breakdown, and improve growth outcome. The composition of early PN in ELBW infants includes glucose, amino acids, lipids, vitamins, calcium, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef67634 \" href=\"UTD.htm?16/45/17116\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Timing and contents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who require ongoing administration of PN, caloric concentration is increased to provide adequate calories for growth. In addition, trace elements, phosphorus, magnesium, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/32/27138?source=see_link\">",
"       cysteine",
"      </a>",
"      are added to PN (",
"      <a class=\"graphic graphic_table graphicRef76606 \" href=\"UTD.htm?12/22/12653\">",
"       table 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Laboratory monitoring is required to adjust the contents of PN to avoid excesses or deficiencies of any given nutrient and to monitor for PN-associated complications (",
"      <a class=\"graphic graphic_table graphicRef56456 \" href=\"UTD.htm?14/27/14779\">",
"       table 8",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      PN-associated complications include cholestasis, line infection and sepsis, infiltration and sloughing of the skin, and air embolus. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/1\">",
"      Berry MA, Conrod H, Usher RH. Growth of very premature infants fed intravenous hyperalimentation and calcium-supplemented formula. Pediatrics 1997; 100:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/2\">",
"      Embleton NE, Pang N, Cooke RJ. Postnatal malnutrition and growth retardation: an inevitable consequence of current recommendations in preterm infants? Pediatrics 2001; 107:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/3\">",
"      Cazacu A, Fraley JK, Schanler RJ. We are inadequately nourishing healthy low birth weight infants. Pediatr Res 2001; 49:343A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/4\">",
"      Ehrenkranz RA. Early, aggressive nutritional management for very low birth weight infants: what is the evidence? Semin Perinatol 2007; 31:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/5\">",
"      Moyses HE, Johnson MJ, Leaf AA, Cornelius VR. Early parenteral nutrition and growth outcomes in preterm infants: a systematic review and meta-analysis. Am J Clin Nutr 2013; 97:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/6\">",
"      Wilson DC, Cairns P, Halliday HL, et al. Randomised controlled trial of an aggressive nutritional regimen in sick very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 1997; 77:F4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/7\">",
"      Ehrenkranz RA, Das A, Wrage LA, et al. Early nutrition mediates the influence of severity of illness on extremely LBW infants. Pediatr Res 2011; 69:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/8\">",
"      Stephens BE, Walden RV, Gargus RA, et al. First-week protein and energy intakes are associated with 18-month developmental outcomes in extremely low birth weight infants. Pediatrics 2009; 123:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/9\">",
"      Hay WW Jr, Lucas A, Heird WC, et al. Workshop summary: nutrition of the extremely low birth weight infant. Pediatrics 1999; 104:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/10\">",
"      Sinclair JC. Metabolic rate and body size of the newborn. Clin Obstet Gynecol 1971; 14:840.",
"     </a>",
"    </li>",
"    <li>",
"     Sinclair JC. Energy balance of the newborn. In: Temperature Regulation and Energy Metabolism in the Newborn, Sinclair JC.  (Ed), Grune &amp; Stratton, New York 1978. p.187.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/12\">",
"      Bresson JL, Bader B, Rocchiccioli F, et al. Protein-metabolism kinetics and energy-substrate utilization in infants fed parenteral solutions with different glucose-fat ratios. Am J Clin Nutr 1991; 54:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/13\">",
"      Piedboeuf B, Chessex P, Hazan J, et al. Total parenteral nutrition in the newborn infant: energy substrates and respiratory gas exchange. J Pediatr 1991; 118:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/14\">",
"      Salas-Salvad&oacute; J, Molina J, Figueras J, et al. Effect of the quality of infused energy on substrate utilization in the newborn receiving total parenteral nutrition. Pediatr Res 1993; 33:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/15\">",
"      Sunehag AL, Haymond MW, Schanler RJ, et al. Gluconeogenesis in very low birth weight infants receiving total parenteral nutrition. Diabetes 1999; 48:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/16\">",
"      Zlotkin SH, Bryan MH, Anderson GH. Intravenous nitrogen and energy intakes required to duplicate in utero nitrogen accretion in prematurely born human infants. J Pediatr 1981; 99:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/17\">",
"      Malloy MH, Rassin DK, Richardson CJ. Total parenteral nutrition in sick preterm infants: effects of cysteine supplementation with nitrogen intakes of 240 and 400 mg/kg/day. J Pediatr Gastroenterol Nutr 1984; 3:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/18\">",
"      Mitton SG. Amino acids and lipid in total parenteral nutrition for the newborn. J Pediatr Gastroenterol Nutr 1994; 18:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/19\">",
"      Schanler RJ, Shulman RJ, Prestridge LL. Parenteral nutrient needs of very low birth weight infants. J Pediatr 1994; 125:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/20\">",
"      Klein CJ. Nutrient requirements for preterm infant formulas. J Nutr 2002; 132:1395S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/21\">",
"      Porcelli PJ Jr, Sisk PM. Increased parenteral amino acid administration to extremely low-birth-weight infants during early postnatal life. J Pediatr Gastroenterol Nutr 2002; 34:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/22\">",
"      Pierro A, Carnielli V, Filler RM, et al. Characteristics of protein sparing effect of total parenteral nutrition in the surgical infant. J Pediatr Surg 1988; 23:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/23\">",
"      Helms RA, Christensen ML, Mauer EC, Storm MC. Comparison of a pediatric versus standard amino acid formulation in preterm neonates requiring parenteral nutrition. J Pediatr 1987; 110:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/24\">",
"      Heird WC, Dell RB, Helms RA, et al. Amino acid mixture designed to maintain normal plasma amino acid patterns in infants and children requiring parenteral nutrition. Pediatrics 1987; 80:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/25\">",
"      Heird WC, Hay W, Helms RA, et al. Pediatric parenteral amino acid mixture in low birth weight infants. Pediatrics 1988; 81:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/26\">",
"      Roberts SA, Ball RO, Filler RM, et al. Phenylalanine and tyrosine metabolism in neonates receiving parenteral nutrition differing in pattern of amino acids. Pediatr Res 1998; 44:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/27\">",
"      Van Goudoever JB, Sulkers EJ, Timmerman M, et al. Amino acid solutions for premature neonates during the first week of life: the role of N-acetyl-L-cysteine and N-acetyl-L-tyrosine. JPEN J Parenter Enteral Nutr 1994; 18:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/28\">",
"      Zelikovic I, Chesney RW, Friedman AL, Ahlfors CE. Taurine depletion in very low birth weight infants receiving prolonged total parenteral nutrition: role of renal immaturity. J Pediatr 1990; 116:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/29\">",
"      Vi&ntilde;a J, Vento M, Garc&iacute;a-Sala F, et al. L-cysteine and glutathione metabolism are impaired in premature infants due to cystathionase deficiency. Am J Clin Nutr 1995; 61:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/30\">",
"      Denno R, Rounds JD, Faris R, et al. Glutamine-enriched total parenteral nutrition enhances plasma glutathione in the resting state. J Surg Res 1996; 61:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/31\">",
"      te Braake FW, Schierbeek H, Vermes A, et al. High-dose cysteine administration does not increase synthesis of the antioxidant glutathione preterm infants. Pediatrics 2009; 124:e978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/32\">",
"      Poindexter BB, Ehrenkranz RA, Stoll BJ, et al. Parenteral glutamine supplementation does not reduce the risk of mortality or late-onset sepsis in extremely low birth weight infants. Pediatrics 2004; 113:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/33\">",
"      Tubman TR, Thompson SW, McGuire W. Glutamine supplementation to prevent morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2005; :CD001457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/34\">",
"      de Kieviet JF, Oosterlaan J, Vermeulen RJ, et al. Effects of glutamine on brain development in very preterm children at school age. Pediatrics 2012; 130:e1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/35\">",
"      Soghier LM, Brion LP. Cysteine, cystine or N-acetylcysteine supplementation in parenterally fed neonates. Cochrane Database Syst Rev 2006; :CD004869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/36\">",
"      Dunham B, Marcuard S, Khazanie PG, et al. The solubility of calcium and phosphorus in neonatal total parenteral nutrition solutions. JPEN J Parenter Enteral Nutr 1991; 15:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/37\">",
"      Laine L, Shulman RJ, Pitre D, et al. Cysteine usage increases the need for acetate in neonates who receive total parenteral nutrition. Am J Clin Nutr 1991; 54:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/38\">",
"      Van Goudoever JB, Colen T, Wattimena JL, et al. Immediate commencement of amino acid supplementation in preterm infants: effect on serum amino acid concentrations and protein kinetics on the first day of life. J Pediatr 1995; 127:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/39\">",
"      van Lingen RA, van Goudoever JB, Luijendijk IH, et al. Effects of early amino acid administration during total parenteral nutrition on protein metabolism in pre-term infants. Clin Sci (Lond) 1992; 82:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/40\">",
"      Anderson TL, Muttart CR, Bieber MA, et al. A controlled trial of glucose versus glucose and amino acids in premature infants. J Pediatr 1979; 94:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/41\">",
"      Rivera A Jr, Bell EF, Stegink LD, Ziegler EE. Plasma amino acid profiles during the first three days of life in infants with respiratory distress syndrome: effect of parenteral amino acid supplementation. J Pediatr 1989; 115:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/42\">",
"      Blanco CL, Gong AK, Green BK, et al. Early changes in plasma amino acid concentrations during aggressive nutritional therapy in extremely low birth weight infants. J Pediatr 2011; 158:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/43\">",
"      Rivera A Jr, Bell EF, Bier DM. Effect of intravenous amino acids on protein metabolism of preterm infants during the first three days of life. Pediatr Res 1993; 33:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/44\">",
"      van den Akker CH, te Braake FW, Wattimena DJ, et al. Effects of early amino acid administration on leucine and glucose kinetics in premature infants. Pediatr Res 2006; 59:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/45\">",
"      Thureen PJ, Melara D, Fennessey PV, Hay WW Jr. Effect of low versus high intravenous amino acid intake on very low birth weight infants in the early neonatal period. Pediatr Res 2003; 53:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/46\">",
"      te Braake FW, van den Akker CH, Wattimena DJ, et al. Amino acid administration to premature infants directly after birth. J Pediatr 2005; 147:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/47\">",
"      Poindexter BB, Langer JC, Dusick AM, et al. Early provision of parenteral amino acids in extremely low birth weight infants: relation to growth and neurodevelopmental outcome. J Pediatr 2006; 148:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/48\">",
"      Valentine CJ, Fernandez S, Rogers LK, et al. Early amino-acid administration improves preterm infant weight. J Perinatol 2009; 29:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/49\">",
"      Friedman Z, Danon A, Stahlman MT, Oates JA. Rapid onset of essential fatty acid deficiency in the newborn. Pediatrics 1976; 58:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/50\">",
"      Gutcher GR, Farrell PM. Intravenous infusion of lipid for the prevention of essential fatty acid deficiency in premature infants. Am J Clin Nutr 1991; 54:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/51\">",
"      Gilbertson N, Kovar IZ, Cox DJ, et al. Introduction of intravenous lipid administration on the first day of life in the very low birth weight neonate. J Pediatr 1991; 119:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/52\">",
"      Simmer K, Rao SC. Early introduction of lipids to parenterally-fed preterm infants. Cochrane Database Syst Rev 2005; :CD005256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/53\">",
"      Haumont D, Deckelbaum RJ, Richelle M, et al. Plasma lipid and plasma lipoprotein concentrations in low birth weight infants given parenteral nutrition with twenty or ten percent lipid emulsion. J Pediatr 1989; 115:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/54\">",
"      Haumont D, Richelle M, Deckelbaum RJ, et al. Effect of liposomal content of lipid emulsions on plasma lipid concentrations in low birth weight infants receiving parenteral nutrition. J Pediatr 1992; 121:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/55\">",
"      Kao LC, Cheng MH, Warburton D. Triglycerides, free fatty acids, free fatty acids/albumin molar ratio, and cholesterol levels in serum of neonates receiving long-term lipid infusions: controlled trial of continuous and intermittent regimens. J Pediatr 1984; 104:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/56\">",
"      Greene HL, Hazlett D, Demaree R. Relationship between Intralipid-induced hyperlipemia and pulmonary function. Am J Clin Nutr 1976; 29:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/57\">",
"      Periera GR, Fox WW, Stanley CA, et al. Decreased oxygenation and hyperlipemia during intravenous fat infusions in premature infants. Pediatrics 1980; 66:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/58\">",
"      Brans YW, Dutton EB, Andrew DS, et al. Fat emulsion tolerance in very low birth weight neonates: effect on diffusion of oxygen in the lungs and on blood pH. Pediatrics 1986; 78:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/59\">",
"      Spear ML, Stahl GE, Hamosh M, et al. Effect of heparin dose and infusion rate on lipid clearance and bilirubin binding in premature infants receiving intravenous fat emulsions. J Pediatr 1988; 112:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/60\">",
"      Drenckpohl D, McConnell C, Gaffney S, et al. Randomized trial of very low birth weight infants receiving higher rates of infusion of intravenous fat emulsions during the first week of life. Pediatrics 2008; 122:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/61\">",
"      Park W, Paust H, Schr&ouml;der H. Lipid infusion in premature infants suffering from sepsis. JPEN J Parenter Enteral Nutr 1984; 8:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/62\">",
"      Rubin M, Naor N, Sirota L, et al. Are bilirubin and plasma lipid profiles of premature infants dependent on the lipid emulsion infused? J Pediatr Gastroenterol Nutr 1995; 21:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/63\">",
"      Spear ML, Stahl GE, Paul MH, et al. The effect of 15-hour fat infusions of varying dosage on bilirubin binding to albumin. JPEN J Parenter Enteral Nutr 1985; 9:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/64\">",
"      Hammerman C, Aramburo MJ. Decreased lipid intake reduces morbidity in sick premature neonates. J Pediatr 1988; 113:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/65\">",
"      Pitk&auml;nen O, Hallman M, Andersson S. Generation of free radicals in lipid emulsion used in parenteral nutrition. Pediatr Res 1991; 29:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/66\">",
"      Helbock HJ, Motchnik PA, Ames BN. Toxic hydroperoxides in intravenous lipid emulsions used in preterm infants. Pediatrics 1993; 91:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/67\">",
"      Sosenko IR, Rodriguez-Pierce M, Bancalari E. Effect of early initiation of intravenous lipid administration on the incidence and severity of chronic lung disease in premature infants. J Pediatr 1993; 123:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/68\">",
"      Gura KM, Duggan CP, Collier SB, et al. Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics 2006; 118:e197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/69\">",
"      Gura KM, Lee S, Valim C, et al. Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics 2008; 121:e678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/70\">",
"      MacMahon P, Blair ME, Treweeke P, Kovar IZ. Association of mineral composition of neonatal intravenous feeding solutions and metabolic bone disease of prematurity. Arch Dis Child 1989; 64:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/71\">",
"      Koo WW. Parenteral nutrition-related bone disease. JPEN J Parenter Enteral Nutr 1992; 16:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/72\">",
"      Glasgow JF, Thomas PS. Rachitic respiratory distress in small preterm infants. Arch Dis Child 1977; 52:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/73\">",
"      Fitzgerald KA, MacKay MW. Calcium and phosphate solubility in neonatal parenteral nutrient solutions containing TrophAmine. Am J Hosp Pharm 1986; 43:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/74\">",
"      Pelegano JF, Rowe JC, Carey DE, et al. Simultaneous infusion of calcium and phosphorus in parenteral nutrition for premature infants: use of physiologic calcium/phosphorus ratio. J Pediatr 1989; 114:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/75\">",
"      Hoehn GJ, Carey DE, Rowe JC, et al. Alternate day infusion of calcium and phosphate in very low birth weight infants: wasting of the infused mineral. J Pediatr Gastroenterol Nutr 1987; 6:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/76\">",
"      Prestridge LL, Schanler RJ, Shulman RJ, et al. Effect of parenteral calcium and phosphorus therapy on mineral retention and bone mineral content in very low birth weight infants. J Pediatr 1993; 122:761.",
"     </a>",
"    </li>",
"    <li>",
"     Koo WK, Tsang RC. Calcium, magnesium, phosphorus, and vitamin D. In: Nutritional Needs of the Preterm Infant, Tsang RC, Lucas A, Uauy R, Zlotkin S (Eds), Williams &amp; Wilkins, Baltimore 1993. p.135.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/78\">",
"      Darlow BA, Graham PJ. Vitamin A supplementation to prevent mortality and short and long-term morbidity in very low birthweight infants. Cochrane Database Syst Rev 2007; :CD000501.",
"     </a>",
"    </li>",
"    <li>",
"     Shenai JP. Vitamin A. In: Nutritional Needs of the Preterm Infant, Tsang RC, Lucas A, Uauy R, Zlotkin S (Eds), Williams &amp; Wilkins, Baltimore 1993. p.87.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/80\">",
"      Zachman RD. Retinol (vitamin A) and the neonate: special problems of the human premature infant. Am J Clin Nutr 1989; 50:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/81\">",
"      Bates CJ, Liu DS, Fuller NJ, Lucas A. Susceptibility of riboflavin and vitamin A in breast milk to photodegradation and its implications for the use of banked breast milk in infant feeding. Acta Paediatr Scand 1985; 74:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/82\">",
"      Baeckert PA, Greene HL, Fritz I, et al. Vitamin concentrations in very low birth weight infants given vitamins intravenously in a lipid emulsion: measurement of vitamins A, D, and E and riboflavin. J Pediatr 1988; 113:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/83\">",
"      Porcelli PJ, Greene HL, Adcock EW. Retinol (vitamin A) and riboflavin (vitamin B2) administration and metabolism in very low birth weight infants. Semin Perinatol 1992; 16:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/84\">",
"      Raju TN, Langenberg P, Bhutani V, Quinn GE. Vitamin E prophylaxis to reduce retinopathy of prematurity: a reappraisal of published trials. J Pediatr 1997; 131:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/85\">",
"      Phelps DL, Rosenbaum AL, Isenberg SJ, et al. Tocopherol efficacy and safety for preventing retinopathy of prematurity: a randomized, controlled, double-masked trial. Pediatrics 1987; 79:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/86\">",
"      Puklin JE, Simon RM, Ehrenkranz RA. Influence on retrolental fibroplasia of intramuscular vitamin E administration during respiratory distress syndrome. Ophthalmology 1982; 89:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/87\">",
"      Watts JL, Milner RA, McCormick AO. Failure of vitamin E to prevent RLF. Clin Invest Med 1985; 8:A176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/88\">",
"      Ehrenkranz RA, Ablow RC, Warshaw JB. Effect of vitamin E on the development of oxygen-induced lung injury in neonates. Ann N Y Acad Sci 1982; 393:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/89\">",
"      Saldanha RL, Cepeda EE, Poland RL. The effect of vitamin E prophylaxis on the incidence and severity of bronchopulmonary dysplasia. J Pediatr 1982; 101:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/90\">",
"      Watts JL, Milner R, Zipursky A, et al. Failure of supplementation with vitamin E to prevent bronchopulmonary dysplasia in infants less than 1,500 g birth weight. Eur Respir J 1991; 4:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/91\">",
"      Ehrenkranz RA. Vitamin E and retinopathy of prematurity: still controversial. J Pediatr 1989; 114:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/92\">",
"      Chiswick ML, Johnson M, Woodhall C, et al. Protective effect of vitamin E (DL-alpha-tocopherol) against intraventricular haemorrhage in premature babies. Br Med J (Clin Res Ed) 1983; 287:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/93\">",
"      Law MR, Wijewardene K, Wald NJ. Is routine vitamin E administration justified in very low-birthweight infants? Dev Med Child Neurol 1990; 32:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/94\">",
"      Sinha S, Davies J, Toner N, et al. Vitamin E supplementation reduces frequency of periventricular haemorrhage in very preterm babies. Lancet 1987; 1:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/95\">",
"      Levy R, Herzberg GR, Andrews WL, et al. Thiamine, riboflavin, folate, and vitamin B12 status of low birth weight infants receiving parenteral and enteral nutrition. JPEN J Parenter Enteral Nutr 1992; 16:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/96\">",
"      Moore MC, Greene HL, Phillips B, et al. Evaluation of a pediatric multiple vitamin preparation for total parenteral nutrition in infants and children. I. Blood levels of water-soluble vitamins. Pediatrics 1986; 77:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/97\">",
"      Greene HL, Smith R, Pollack P, et al. Intravenous vitamins for very-low-birth-weight infants. J Am Coll Nutr 1991; 10:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/98\">",
"      Bhatia J. Palliative care in the fetus and newborn. J Perinatol 2006; 26 Suppl 1:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/99\">",
"      Greene HL, Hambidge KM, Schanler R, Tsang RC. Guidelines for the use of vitamins, trace elements, calcium, magnesium, and phosphorus in infants and children receiving total parenteral nutrition: report of the Subcommittee on Pediatric Parenteral Nutrient Requirements from the Committee on Clinical Practice Issues of the American Society for Clinical Nutrition. Am J Clin Nutr 1988; 48:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/100\">",
"      Zlotkin SH, Buchanan BE. Meeting zinc and copper intake requirements in the parenterally fed preterm and full-term infant. J Pediatr 1983; 103:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/101\">",
"      Darlow BA, Austin NC. Selenium supplementation to prevent short-term morbidity in preterm neonates. Cochrane Database Syst Rev 2003; :CD003312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/102\">",
"      Lockitch G, Jacobson B, Quigley G, et al. Selenium deficiency in low birth weight neonates: an unrecognized problem. J Pediatr 1989; 114:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/103\">",
"      Kien CL, Ganther HE. Manifestations of chronic selenium deficiency in a child receiving total parenteral nutrition. Am J Clin Nutr 1983; 37:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/104\">",
"      Van Caillie-Bertrand M, Degenhart HJ, Fernandes J. Selenium status of infants on nutritional support. Acta Paediatr Scand 1984; 73:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/105\">",
"      Schmidt-Sommerfeld E, Penn D, Wolf H. Carnitine deficiency in premature infants receiving total parenteral nutrition: effect of L-carnitine supplementation. J Pediatr 1983; 102:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/106\">",
"      Bonner CM, DeBrie KL, Hug G, et al. Effects of parenteral L-carnitine supplementation on fat metabolism and nutrition in premature neonates. J Pediatr 1995; 126:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/107\">",
"      Pande S, Brion LP, Campbell DE, et al. Lack of effect of L-carnitine supplementation on weight gain in very preterm infants. J Perinatol 2005; 25:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/108\">",
"      Kumar M, Kabra NS, Paes B. Role of carnitine supplementation in apnea of prematurity: a systematic review. J Perinatol 2004; 24:158.",
"     </a>",
"    </li>",
"    <li>",
"     Nutrition &amp; Gastroenterology Clinical Review Committee. Nutrition support. In: Guidelines for the Acute Care of the Neonate, Adams JM, Garcia-Prats JA, Schanler RJ, et al (Eds), Newborn Section, Department of Pediatrics, Baylor College of Medicine, Houston 2002. p.43.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/110\">",
"      Martin CR, Brown YF, Ehrenkranz RA, et al. Nutritional practices and growth velocity in the first month of life in extremely premature infants. Pediatrics 2009; 124:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/111\">",
"      Blanco CL, Falck A, Green BK, et al. Metabolic responses to early and high protein supplementation in a randomized trial evaluating the prevention of hyperkalemia in extremely low birth weight infants. J Pediatr 2008; 153:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/50/27434/abstract/112\">",
"      Cronin WA, Germanson TP, Donowitz LG. Intravascular catheter colonization and related bloodstream infection in critically ill neonates. Infect Control Hosp Epidemiol 1990; 11:301.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5026 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-211.167.112.17-380DEE3FB3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_50_27434=[""].join("\n");
var outline_f26_50_27434=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GOALS OF PARENTERAL NUTRITION (PN)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ENERGY NEEDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GLUCOSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      AMINO ACIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Composition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Cysteine and glutamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Early administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LIPIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      10 versus 20 percent IL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Continuous versus intermittent infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      New lipid formulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OTHER NUTRIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Calcium, phosphorus, and magnesium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Recommended intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Vitamins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Vitamin A",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Vitamin E",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Water-soluble vitamins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Electrolytes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Sodium and potassium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Acetate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Trace elements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Carnitine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Route",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Timing and contents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Composition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Administration and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5026\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5026|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/46/42733\" title=\"table 1\">",
"      Nutrition needs preterm inf",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/43/25275\" title=\"table 2\">",
"      Caloric balance PN preterm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/45/17116\" title=\"table 3\">",
"      Early TPN extremely premature infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/27/15805\" title=\"table 4\">",
"      IL formulas preterm infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/28/38347\" title=\"table 5\">",
"      Ca P Mg needs PN infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/22/12653\" title=\"table 6\">",
"      Vitamins PN preterm infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/54/12141\" title=\"table 7\">",
"      Routine PN preterm infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/27/14779\" title=\"table 8\">",
"      Lab monitor PN infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/8/19593?source=related_link\">",
"      Approach to enteral nutrition in the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40567?source=related_link\">",
"      Calcium and phosphorus requirements of newborn infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24039?source=related_link\">",
"      Epidemiology and risk factors for Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23912?source=related_link\">",
"      Growth management in preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37816?source=related_link\">",
"      Neonatal hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/23/26999?source=related_link\">",
"      Neonatal hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=related_link\">",
"      Neonatal hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21736?source=related_link\">",
"      Overview of vitamin A",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18730?source=related_link\">",
"      Parenteral nutrition-associated liver disease in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31992?source=related_link\">",
"      Short-term complications of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=related_link\">",
"      Treatment of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29753?source=related_link\">",
"      Zinc deficiency and supplementation in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_50_27435="Diagnostic criteria Churg Strauss";
var content_f26_50_27435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        American College of Rheumatology criteria*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lanham criteria",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asthma (a history of wheezing or the finding of diffuse high-pitched wheezes on expiration)",
"       </td>",
"       <td>",
"        Asthma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eosinophilia &gt;10 percent on differential white blood cell count",
"       </td>",
"       <td>",
"        Eosinophilia &gt;1500 cells/microL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mononeuropathy (including multiplex) or polyneuropathy",
"       </td>",
"       <td>",
"        Systemic vasculitis involving two or more extra-pulmonary organs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Migratory or transient pulmonary opacities detected radiographically",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paranasal sinus abnormality",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biopsy containing a blood vessel showing the accumulation of eosinophils in extravascular areas",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Four of the six criteria needed and biopsy evidence of vasculitis.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     All three criteria needed.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_50_27435=[""].join("\n");
var outline_f26_50_27435=null;
var title_f26_50_27436="Drugs that cause weight gain";
var content_f26_50_27436=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F57541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F57541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs that cause weight gain and some alternatives",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Category",
"      </td>",
"      <td class=\"subtitle1\">",
"       Drugs that cause weight gain",
"      </td>",
"      <td class=\"subtitle1\">",
"       Possible alternatives",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"3\" rowspan=\"1\">",
"       Antipsychotics",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Conventional",
"      </td>",
"      <td class=\"sublist_other\">",
"       Thioridazine",
"      </td>",
"      <td class=\"sublist_other\">",
"       Haloperidol",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Atypical",
"      </td>",
"      <td class=\"sublist_other\">",
"       Olanzapine, Clozapine, Quetiapine, Risperidone",
"      </td>",
"      <td class=\"sublist_other\">",
"       Ziprasodone, Aripiprazole",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lithium",
"      </td>",
"      <td>",
"       Lithium carbonate",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"3\">",
"       Anti-depressants",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Tricyclics",
"      </td>",
"      <td class=\"sublist_other\">",
"       Amitriptyline, Clomipramine, Doxepin, Imipramine, Nortriptyline",
"      </td>",
"      <td class=\"sublist_other\">",
"       Protriptyline",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Selective serotonin reuptake inhibitors",
"      </td>",
"      <td class=\"sublist_other\">",
"       Paroxetine",
"      </td>",
"      <td class=\"sublist_other\">",
"       Other SSRIs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Other",
"      </td>",
"      <td class=\"sublist_other\">",
"       Mirtazapine",
"      </td>",
"      <td class=\"sublist_other\">",
"       Bupropion, Nefazadone",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anticonvulsant drugs",
"      </td>",
"      <td>",
"       Valproate, Carbamazepine, Gabapentin",
"      </td>",
"      <td>",
"       Topiramate, Lamotrigine, Zonisamide",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Antidiabetic drugs",
"      </td>",
"      <td>",
"       Insulin, Sulfonylureas, Metiglinide, Thiazolidinediones",
"      </td>",
"      <td>",
"       Metformin, Alpha-glucosidase inhibitors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Serotonin and histamine antagonist",
"      </td>",
"      <td>",
"       Pizotifen",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Antihistamines",
"      </td>",
"      <td>",
"       Cyproheptidine",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Beta-adrenergic blockers",
"      </td>",
"      <td>",
"       Propranolol, Atenolol, Metoprolol",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Steroid hormones",
"      </td>",
"      <td>",
"       Glucocorticoids",
"      </td>",
"      <td rowspan=\"2\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Progestins: Megestrol acetate, Medroxyprogesterone acetate",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy;2001 George A Bray, MD. Reproduced with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_50_27436=[""].join("\n");
var outline_f26_50_27436=null;
var title_f26_50_27437="Drugs that induce ILD";
var content_f26_50_27437=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug-induced interstitial lung disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Antibiotics",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Nitrofurantoin, acute and chronic",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sulfasalazine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Minocycline",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ethambutol",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Anti-inflammatory agents",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Gold",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Penicillamine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Nonsteroidal antiinflammatory agents",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Leflunomide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Anti-arrhythmic agents",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tocainide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Amiodarone",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Chemotherapeutic agents",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Antibiotics",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Bleomycin sulfate",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Mitomycin C",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Alkylating agents",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Busulfan",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Cyclophosphamide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Chlorambucil",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Melphalan",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Procarbazine hydrochloride",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Antimetabolites",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Azathioprine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Cytosine arabinoside",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Methotrexate",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Nitrosoureas",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          BCNU (carmustine)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          CCNU (lomustine)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Methyl-CCNU (semustine)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Other",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Etoposide (VP-16)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Paclitaxel",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Docetaxel",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Thalidomide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Nilutamide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Alpha interferon",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Gefitinib",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Drug-induced systemic lupus erythematosus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Procainamide hydrochloride",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Isoniazid",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hydralazine hydrochloride",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          The hydantoins",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Penicillamine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Illicit drugs",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Heroin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cocaine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Methadone hydrochloride",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Propoxyphene hydrochloride (Darvon)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Talc",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Miscellaneous",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Oxygen",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Drugs inducing pulmonary infiltrates and eosinophilia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Radiation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Statins",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          L-tryptophan",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Bromocriptine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Bacille Calmette-Guerin (BCG)",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Rosenow, EC, III, Martin, WJ, II. Drug-induced interstitial lung disease. In: Interstitial Lung Disease, Schwarz, MI, King, TE, Jr, (Eds), Mosby Year Book, St. Louis, 1993, p. 255-270.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_50_27437=[""].join("\n");
var outline_f26_50_27437=null;
var title_f26_50_27438="Survival after transplant IPF";
var content_f26_50_27438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Survival after lung transplantation for recipients with idiopathic pulmonary fibrosis (IPF)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 295px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier survival after lung transplantation for recipients with idiopathic pulmonary fibrosis for transplantations performed between January 1990 and June 2005, stratified by procedure type.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Trulock EP, Christie JD, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth Official Adult Lung and Heart-Lung transplant report-2007. J Heart Lung Transplant 2007; 26:787. Copyright &copy;2007 Elsevier.",
"     <br>",
"      <br>",
"       For additional and updated information, please see the International Society for Heart and Lung Transplantation slide set \"Overall Lung and Adult Lung Transplantation Statistics,\" slide titled&nbsp;\"Adult lung transplantation Diagnosis: Idiopathic pulmonary fibrosis\" at: file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_50_27438=[""].join("\n");
var outline_f26_50_27438=null;
var title_f26_50_27439="Echinostomiasis egg";
var content_f26_50_27439=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echinostomiasis egg",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 300px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEsASwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6fBATHpTQQWGaazY4zxTFfPTJoNLEmMMRSrTIpQZGibqAGHuDUo65oEK3AwOvvTYyxAL43AYOOmad3zTh904piIgi+cMLksMk0GM5OXBPt0FPDBUz3NM2kHHbtSsMVAYicHIPWp0IPNRspKke1PRMKPXFAmKxBpjnjrT9vXFQS5HB+tICtK+DmqksuM8mnztyQazbmXAI96llIdNcZ4HWoluv9qs6e52tnOMjFZ8l4VPJqLlpHTJejHXmpVvB1zXJi8wck1PBeHdndQmDR0NzKZE54BrD1COJvuDI6ZPepXu8rgnNU7mbA6UPUS0MG7hjScso5rS0y428HtVC+k4BHrUUEvI7UWKPQ9KugVXJ4NbsTQyryFNeeaffLHxuOa6Gz1DIHNNEtHSLbxI25QKfvABFZiXwJ69qin1ALyvJ9KYkrl24brnoaxbjmfcUJYKQD14qS4vAeWZwxHA7VmvfGdmjVGRgQoOaTVyloTF4goABB7k+v0oEIwS3JOKhQOf9YBv71djdQoVhjnJ/xqbDEW3UD5VGTx0pZIRGoAI5p0bATM2c88A5xUxjDvuGAo4+lMTIIYgoxU6ouKQoQME4x0pJZcKcUDBoxis2+h3Fj3A/Gr4lz17iqVy+QdxouKxz94NkJdjjjBB9awHRGbJIroNVwyHJ61zMh+c7utZNGi1PbAqtgyPjPQCl+TgruHv2qJ52YnGOPak3YPA69q6jGwtyp82CZDymVb3U/wCHBq4vPIqqrcD1/nUyccdu1MlkwpevTgdKYCPxpGRWmRznK8AA8c0CFQfNg+lSKNuRSKQ3TFOU/jTAbboyId53MT1qYmmjuKD+tIQmcE+lV7huOan6k1UueAaBpGbdNjNYd+zDp0zWxOd4JHNY12DtbPWoZaMe9mIBPcdqx5LnBwa0b7gGsOfkk1mzRE5uc9DUkV0wPFZLMRTo5RkZpIGdDFeE4B4ps9zuJGayVlAGQaa82eapEsszzBic9KqtNjjmonmxyKhaQ4470AjTspzvBY8Vv2NySwBPFcnbEjufatzTptuA/FMDojcEdKiN2V+Y5IqKNg6nbSiLcvPHNFgLtrcq7Dceo71ZkjiEu5W6jHB4rLWIqwyPyrQhiPBJJBosBIFU4b+I1ZiI4AB9TnFRrGRwAcVOi4A4pFEoKqSDyMc/Wo42Yr8wx6CpFVgQvQGh+vHenYRDKzdzk+9VZJNoGTVqYjHPWs64ZRnnmgQjXAQkk4FU57xCTzkdqqXF0u455A61RmuBgjpUMtD9QkWReO9c9cKfNOBVya4yfWs+W5G85qbge3xWzCEF0KuO45zTl249atyxtldp5XpzVYgJMcDlq6UY3uNPLk4wBUyEEdKY4+cAHgdal7dM00JjgufrS9uelIpz2qQDPPagQxRjJBzmlHBpzsFXngUkmTgIOT3pgPo59aZEGHD/AHqeelAEF0s3lf6OVEmf4hxVPUGKxkZAkI6fzrTfse1Z92UeUhhuwcg+lIaKaoWj4GMCsu8iwDjmtp/kbA6E1XuoMqKhoaOLv4Dlsg1h3cGM9K7S8t854rDvLQsxxUNFo5SWJskE8VAAQeQa257VlPSqkkOWJxg0irlZG4xTJiccdastHhelQSK2enNAik7sDzTRIW4pJQd/JqJsjAqhGjbSgDnrWhBOcBq58ueMVYjlIGATxSGdfaXmFAz1rZgmDIOmTXDwXG1VBNb+mTkhQTmmgOrjQOATzV2KFQOOtZtnITjPetiI/KMdKBDoox9amWPnpTo1796njAJxTAreWRzTZoyR0xV5lwcD+dRyA7OFH1osFzIlUYJOPWsu+wASoOPpW1MpOevHbNULqJnB3EY9AKLBc5ByqyyLJkA9Kp3sbIgOeD05revrPcTtBHvWHPZyJlmYkCocSkzDuZCp9AKq7t3IJrTvbdWGR1xWcYipxg0hnv7ycRvyX2jJHSnE7lWTq+elShFZNoGT+WKQDChFHzD0rcwYyEh3Z9uBnoan2hutRZXeMDnofQ1KvHFO4EgGKUUwNk80uRzTEOwGBFNPDAjtxQHyeKcMk8UAAyWBpxoB4o9KBCFciqrIFjKsnOc5HerhNQvl2IH50hplIcthh09Kc8OQeM4GKubVjAVRzjrUYbDHt2pWGmY9xaZzgVk3liSTjI+ldaYg1VJrTc2SKTQ7nEXFiSelUpbL2zXdT2APas+aw4I9Khoq5xEtrjtVGe39OPWuyubHrxWRd2RGfagZylzb85rPuI+P5V0d1BtzxWDeqFyMdeaVh3M3kMetW7cHiowoJ5HNXrZBnkfpTZKFVMsCOpre00BNvrVO1tfMfnpW1Z24VhwPxoKN+w6Dgmt22Hyj9ayLBSF4UD3rZtlOAB0NNITLUQ4q2i4FQwIc1bQY607EjXX2qtJk/wD1qtv09qrTDrzketMEUbhfSqTRnOeTV6Q5J9KgAwW/SpZSRVntVd1UdTWNqFlgnpj+ddGfus/AxmsW9n8xCp5I/Skwv0OSvYBuKrxist7QscktmukniVm45GKh+x5A4qSttz12T1BxVV5dj9uR0FVr672jC8/Q1jXWqYIC9V9auTM1E3TLGOo5606KbeCxP51yb6qxAQA7ieK1rOVmjHmNjPampdwaNd7lSOOo9ar/AGvc7DBXbxzVYDziSrkY6cdaryyOswVx16U2+wlE2I5snFXI2GMcmse0YkjHXFacJaqTEy0OlB6UDpS5oIG/Wo4z+9ZT9RUgqOVQcMO3pQMVl5JoRBzkUI+YwXH096eKAGxpgHNOKilAwOTS0BchkjznjNU5YiQSRitKo5IwwpNAmYF1B8oOMVi3UOWYAcgZNdXdRfKQ34e1Yl3CVcuvPHapZojkbyHO4Y/OuX1K3yCccrXb6mqIjFvlz61yequCjeWv/AjUdS0YMSJu46mtS1QbhxWWIzv9e/FatmGUjJptCRuWS5GAPmPAH9a3rK3QDlRnNYumths46101iu7GRTQGhawgAccVqW8YGGxnFQ2yjaABWlCgwMVSQmx0Y9sZqXHHpQFFL25qrENkZqJ8belSSEg1WkkAIBzjvikykQlAQeKrtETyKsNKMcY6VXe4CA55qGWQMpVZATxisprUMGI4+lTz3y+YRng1Ja4bOeaQkjGWzG/vkHirKWMjLxjFdJBZrIANmAec1dWxjUYwPyppDcjz+fVQyZaXB7AVkXWqBiCpySea566unBBXt71VS6Z5OePakLY62C7kLo4xkV0Fjdyyr8xJOOo7Vx+nu7Fc9K6W03quMcHmhaAzobYsiDnIFXGj85UY9azdOBYr5oBAPTtW1AVklAVeMcY7Va1Ieg+GHCbgdrA5wehq7GwDc4BpIU3IOPzoeIFgcZxzVC9S0OlIeDWRquoz2l7ZRRW7yRzNh3Ckha1WOOlF1e19SUpbtafmN3Zbrz6U89KaOppJZEhgeSVgiKCzMTgADvQMkUd6dXmGu/EG8ldl8N2sTWqglr+6yFP+4nVvqcCsAal4t1KRJY72+ljYdIIhBF+DHr9azlWhHdlqlJnt1FeIG18bAeZFdssYXcc3JlP86tWOueI7ZSZtUcFRyJYTj9Qc0lXpPqHsn5/cey0V5paeOdSjKrJHZ35IyVhYq4/Cuh0jxtpt+qicS2ch4xMOPzFaRlGXwu4nSkttTo7hNwrHu0xk4raSWOWMPG6sh6MpyKqXMIYMccHjFJii+hwXiOJpNqohY+ucYrh9aaZWAO4JnnHSvT9Tg6+9cjqlkZzsC/u2OD9KjZmlro5bT4GmBbkgcc9614LZlZRjmr9jpCW8RCDIznJPNaNrakNleD9M0wILCF1lArqbGNmjGQM1mx2jsBsJU9STzWxbbYVG9ssR371SQNmxaRFUB79xVzzI4xgtzWXBcNMNtsRkcHPb60S27K8RYnex5DNgVXMkS4mvHIH4FSY461FbRsiAPgmpXIC0JkPchn5IBIVe5qi672IXOOxNWrqMuUy33TnNKu0Rkd+1Sy46Gb5JDOM/NjAzWPqNx9n++QoxyxNbmp3cVtF5hIz2964HxfcSSxkMVLkhgowMjvWdrs05tCzConlBDcMeuciut06z2xJ396838MW11qE5ePJVSOOgr1vTrWSBP3j7sjgYxiqUSZS0LUKbVGetS4FIOlLWhi2fN87Fzhh3x6UyKMgkjGQcc962rizDkkA9agW1PmKCDjoRWN7GzRa0xhwp6+p9a6awfPXpWDaW20/MOOorWtyV78CgZ0UBDAdCfStaFngRZSOB3Fc9arIxXy2Rsn6EVp28xWGVZT1BXjuaqL7EtW3Nu2uSflbIYnPPcVoIMAetZIMiW0A4IyBnHI49a04vu8Va1IkiRgD1ANNOQeKeRxTadiUMzySeTXm/j/U7vWtUXw9pOSvWd/4SPQ+w9O59q9Fu3ENrLMTxGhb8hXjEUyQ2k+pyyorvebdrkjKgcn3AJ6CsK0+VWRtRim3Lsadho+jaZppukX7RexA7nvyWEDL947OgI6AAdelZ767q0kkU7NaTREkiKZSGA69QcA49q6C0itNQFzLNGBJcpiQFiQSV689gPWuBkukt2kjys8a5EbDOCMkZPPTj+lcUXGTd9ToalFK2h0F5r8d7KiQyeWrJuYgmMp7Zzz9KW+1SPT9jzMLlyuAm/sO59B2z1rltPCXF8QwAcFii849T14HpVW5lSTUZeQqBeBjGcHnkGhxTdh80krlvUdTjUbpUileQEhApAjPY+p/rTLfWLhIhHHaRFDxuLsA3v6VkB48GQSEhwTsYcDsPw4q3b3zH7PDLsQE5ZguWIHc/yqrITbZ0/h7xDeWkkaRXSRTMxIhydrgfXj8q9J0TxZBfhYb1Rb3J6An5W9wa8Tkma4JUfu/LffEwXaTx1+tdVaYu9JiumChuQ2OCCOn/AOutVWa+IOVS03PRdQcyXBVMEA4NUprYFfu81z+h+IoLe6W3u3Dox4kxypA6E967kQrOgaMhlbkEdxW176mUocu2xgpaZXk5FSRwBWHGBWsLUqfake255FUiWU2icLiMfWnpbiVSZEy8bZz2xSmWS1kDOpMRPUVOkZvCzQuQhI4HfimwRo6T5S+YoC8cFvWr0+JBswMd8+lZZAjl/dxjdjBPvU0ME8rZZtoByBnNCuS1rcuxMRGQzjjvTJZwI8gg/SmizSNGGSd3Jyain2INuRg8iqvYSSHediIB+GNQ3LiO3MjuVAHBzVR382T72McVjeKL+QWctrZM32gKCcDOFyMke+Ki5duxQ1HVVkklVCM7cqxzhT/n+VZUMT3MXnkrclRn5SC2D6jt9Kp2CmedmlkYxEghmGT7/wAqljcWUU+0lU4cncRn29yaT30D1On8FzwpbGb7PKADgErwSD0rvYm3xqxGMjOK5P4dXv2ywvCIwI1mOxgchgR/OuvrSKsZ1HcKKKKozPOpdMQy4x14zWdPpwWQ7OMfrXbz2q7ixGDWfJCokO9QV65rF6G61OaS1ZCpYcY4qVEXcAQa1LpR0VRimLb7sEDpSsVcrRROHOwkd62LKLYAxG49TnvSQ2xZQOlWzC/AwwHByKuwrltI5JAhJG1TnaOBmrcaPxg4FR28XmRkq5DKcD0NXIuVXIFWtDJsWMEffbNSYFAFOFMlszfEJK6Ffleohb+VeL3lqt1p2n7ohLcQSSymI8LIN3t3AH0r3HUIhPYXEX9+Nl/MV4i+n3b28Rs5WaYSHcoOWUD0+vpXJie500PgfqipHdy2iyWcbySm4kwd8g/d8dFA6j+tZt1b3TWrLLIzxgsVZgFXAOOw5q1b2txbaheE+WZowVVeFcfn3+nNVnjX7BJcyE+XG4SS3Zjlgf4s+/U44rmvY2sUlmeGYrNIrNkKxXIK/wD1qgMbzXgI2quSSd4OB7VflZZYwFt5tijy0OAV69PpzVN4FA2/KB94g8k+lFx2IFiRT+8YOx4AC44pYGVJSrD5VGdvbGadK22XoC2MDjkCqzIvyldwz29801qLY1JZIoVVgoZS2QeD9as6dNIu14Z87sPsbOF5/U/pWGRMFfeQR1J245rRtJtkCFZPLYnI6EnPFNbCZr3bmREfDYGfmK4JB7jHQ12XgrX2tmit7py9rIcKSOR7/wD1q4O1eS4t8x7EYLyFOARxwPUmpws1uEdxKII4wjsjY25PUepz+maqE3HQPU+gREr7SMEdc+tJ9mGenBrl/AOpXEllHa6gSZ0UYYnOR/kV2ODnOTj0rtjZq6OWd4OzMqe0wSPvIeCtVobP7KTJA5X1X1rcMYY5yajliXHSm1cFMrwL5oBbjvVtnVEPNZM90LdjzgD1qnd6sojyp5qb2KcbkuqaiwDCHJCqWY4xgDvXJ6vr01rIm/kN90Hg4/pU1/rHmMFGDg5xx1rldTlmukdnCoCflHXcT61F9dS7WN6219+doPfr61S/tKI6iZZWcl1AGaxhYu6ZRsfKGxuJ6enpSXEMiuEkGABndQ2mC01OogW2MJkjIKkknPck/pTZFs7q5EMyho1Xsx+XpzWE98lu0aSMWjGCu329a1NNAmleZjhWGdxHU0l3C53mkeTptpHBYwosROTs569zW+sitwGBPpmuLtNQkKLE0QGTgBT1NUtTnutGmaaBnfc33scYNXGXciUbnoQcHoadXBaT4pZw7akwRwQAqL19q7C0v4J7dJFkBBHetEzNwsUribGADmsm8nXLZPNR3N4cnmsW5ud8+C3vWbNEjUW4RlPTGODUtm6sB6ZxWDJOqrjdmrNnc7U4PI7nvSQ2dZb4BAByavhfu5HJ4INc/Z3WSPpzWza3O9xxx0rVENFtIQM7cgegqyqgLjFNRhUmeKZDYwHkj0/WlAwaVWDDg5pTQSIRkEGvKJ9OeHXNVszuKKDKoOB8ucnHvhhXqxIHU1xfjGB7XUrPVIkyudkn0wc/oT+QrDERvA6cM/ece/6HmupF5bu/P2gOUkIYeZh8LnBx74z+NZSIksiyLHIMAY83neD2H0NaOsxNputahBJJEiO5RSTkvG43KVAHPHHPeqMn2hrBNsDIqnAHGQefvevGORXFayNk77kM1yTkySKMsQynqCM/rWdLIRLlJAy4DEenHTmlvAbZzI0ZYsNwHUrnv71lsxSUluATkHHHPfimlcbdjUimEgfcDuxjnn8aikkwv7sbcDPy96hcHb3Y5P8AFyQaXnYnO1+hBpWC+hPbM0uCR1zyecVppFD5XzKu3khhyd3TFU7AKw2M21h3HXA61LPcNAHwUYkjBxz060r66FdCdFBRT5mduQdvUAZOf0p93FvsQ8IyqoQoBxgn8azJWZ0WSQ4bnO0YyT/OpbZZbfySGcRE7toHBPr+GatEM9L0yTDwTwyEXIAXy1JPCjnI7etemaVeLfWUcykEkfNj1rxjQ9dvf3sNyiCEMBlI8P056da7TwLrKve/Y9xMbqSrE8H0wO3etcPNxfKwqxVSOm61O/qKc4Q8E1LSOMqa7TgRxGvufMZTkg8cdqwJpHOFLEgetd1qenxy5Yr83rXOXdlGrEMKxludMXoc7KibSQMnOAfes0GSRmj3BSBjnjvW1cRgNjqmf1qOOxKsHYjrkqPT6/0qCivZ2sjFVDqUH+1k4rTjsbSUGNmDtjv1IqexswCrSAGPJK44OcdDVmzk89GZ7WSIAlTIRjcO45pasL2OM1bSxDcERsBGCDg9ee1bWlWzWdtl4n8lyOM9K0Lqe1gQE227JAz14Hfn61lXl6fLPlMNgHK96taol6GnC8aOFEj8Nnjg/nWpdXdmLVSTNIxYDCjt6+9czYRvd4ZRluwzWiBPp6ZuHVgo3iMcn8KdrBe5NqFpb2couJJtsj8hieFA9qoJr0KbhHK0i5+8vQ1jveXGpXj79zR54PUgetNg0OQqxt5kCbjwT0NPyJN6/vMAhTzWVJOc5J568UXr4J55rKuJ8gDmkxottc9eSRVmyvD6c9qw3mKgVJa3JJGM0tR3R1UeqGLtk1vaVqDuykd/TmvOyJ55AM4AP5102hqVByWDDoRVok9Gt5ty59ecVejcMKxNPbcqseG7+9bEeMACtEZsJWaPBRC+euO1SA7lB6DrTs8c8UwEAcc80Eg3AzVPV7X7dp8sIA3EZXPQEdKuE5HB/OkVgGx3NJq6syk3FqS3R4l4i0GXUbiG5jYLe26G1bcenXy2I6Ecsh/nXHWt5eRC7srtCpL+WZWB+8o6Z7ele3eLdNEFz9rjTME4KTqowTkYPPY45HuPevI71D9ouI2DyTpIYnkY/u3PUSfXH6muCSaumds7O1SOz/Pt/XQx7xd0TMVyQMbck7fQD19aoOitwrHBGBlcVorAzhVZ8bjkMB1/z0qpdxCFxlyHOTzxxUrsISP92QeCT0zx+NTKzPtZSOSRzyQaqqeFUqePyINKMRk4ztXGKTRV7F9MsRhyzYxhe2O9MmYDy/LAY5OSfamx5aMEDavQ46r61GZV8rbtxkHaf9rp3pWHckkkeNGw2c+nf0q1FcyDegZmVYwoU9Tnqc1mquT5aN87nB5z+P1qzJaAY89zEnQKf4sf5NVZdSbvobFrqUls0Hls7SuoJRvukjGMHtg810fhi6C6a2oTTrFdxShUiQn5xuJ6fVuPYVxsUauyiAKWQgbjz0wfxNdroNpHEzQMC1xcgZZWztYj374I57EUrpFQvzbns1pMLi2imXgOoapScGsPwbcefoqAliUYr83Xr/8AXrcb36V6MZcyTOGpHkm4lS8I2HkfjXN6h8yll6iumuEB571iXsRGUIPzcjuamSuXFnA3VzNJK6lhGqtjIyCc1Lp9yNhWWVNinpySG+tWPEFoba8+0YKwMDk4OMj1H1rGu50ZkhtFyAcNJjAz/hU8pXNqdNaapaiGNZR8yfdbAG72NX7y5+3wqkUyeUeXbd+Qrz4PdKsh2JIo+VSp6VNpsk6XsMDcxythlPSly9Q5jpJvJkJSRiT0GFIx9aybqweMeZlQGOOfyrp73So7WzEqS7yVHyDoMd/w965qaIyTAHJQH7x5zTjuD2N3QrbMahQeOAavatbHbiTcZQu1Qo5xg81q+HbNVgUhQDgflVzUdP8ANbfghsYB5x9Ktx0I5tTy/T7QwTF5pFRXb7qjkVsQaHFex+fPe3cDN0RAMY7dq3J9CXerBFPOSAeM1oQaeqxAMuT9alFtI80vC0mSqms9kbBbpWxNEoDbuWHpWcwOcYOBUisVWjZRwN3pUaIyEsB361q/KAAOuO9OSENzxxxii4WILV93DDK10WjKS5zwB1xWSkIjxgcntW3paYYde1WvITOv09wAo7VspJtGOMnvWBYuAcDP1rUQ7mUjoe9WmS0X1fd0o5HQVEhzgA5I7VOBxzVEPQjOSfb2pwBHWl4HajPPUUAV9QjhlsnjuATGwwdoyR714z4ut5NDvmkkgD2zna5K54I4OPT+X4V7Vz+FZfiTRINasDGyr5yg7GI/Q+1Y1IKRvRqJe5LZ/g+54BrMTWbxKsOIZV3q3G5CQeM+maq3NvCts0qx/OCBtOSVGPWu/s1h09zpuvkfZ4QxTcuWHX5fzNcjf6YdSlkuNIUwadtDMzMTuZefu9hXFs+V6WN3Fp2e5zhXJkd2Y4PQcH/IqGWRhhweh57j61rXNpHGm1ZG6/P8ucj2qj9meRH8oBUJwQfXriq0J1C1mYRjLsSScKBxnHelmJIQll2/3fQ/SovmiQOOYt2cqelTw24vAWcgAAtgscnmlZJ3Gm2rEsMB8uVhJhF5DEYP1NadvqMMto8cqIzBcLu6cenvWYZGKeXHg7BgnGOfTmorSOSRJF8tPMb7jHJB+gH9aXLfcd7bGhbzCWZTBAm+STB3fKoJ6HPb+tdXpv23VnZ/tX2YxxCMuo3MxLHIUf1rmLHT4woSdyo3bjEv3nGMNj3/AJV1Ojag1jKl3axATkfZY2kfAKtjk4z8wIB9M55qZNdBpdz0P4cOf7OkicnzIyUfcTnIJAzn2xXXPnPFcR8PpZJGknmXa9wzlxnOCCDjn2Nd0MV3UHeCOXEP95f0Idpz83SsjWIb2CeG7s41nSNsyRbsMw9B2/Ctw4J+lOxWxlc51lsfEds2+MJKFztf7yE+orGsPCxtYZAwWeYMQT0AHbr3rqbmy2TPc2qqJGXay9m9/rWLqGrRGB4slZQvlu27Bzn9aiWiLi77HNJoT20kUl0ohjncAgMBtGex9a2LvSbX7TCbaSSeVdoEpx8gzgDpg9aghaW8uY4YJFe3QEorx5GfTNdTpemi2RfLwIzhmQ9iOw9BUrUqXmc5faffxyMkhZ4m5De9U4dKMk5YDIbHHv6V6BPAky4YVBHZRRSDYnHr6VfKSpoXTbcQW6DvirmBQBik3DOM81Rm9RrImORxVSUKr4UDFW5MngHAqIwx9wT75NIpM8WnuFzgtnPWog25jg1mvICxI471oWRyR79/asbG1ybB2jI461KrDGB19KnWEFflNIYGH3RmjcaJ7VN7hSQCf51p2eVYg8ODj2rPtUZAM8HNa9odySBhhzjb+FUiWzasCWA8wlK1Bkkqrds1jWW9huY49h2rVhYbcKCWPUmrRLLyzLEse5TyMbverQODjmq1v/00Ukg+nSreOKozegh5PPSkJA6AUjPtOD34FR5LDJ9+9O4Dm6YH4URt8v41DLJsZMY2k49x70rvhgAKQ7GN4o8OwavGJowqXsY+VyOD7GvLLmS70u7gsL23W2jjlOJGbAyRgZ7d+pr29MlgWOFrL8RaFZa/ZNDdIN2MK6jkf/WrGpSU9zelV05Z/J9v+AeKDTpmZru+hhlmkkYERNhgOfmIzgD369KwbnLSu8rAQ9CAdxJHG0n6jtXaax4bufDEwuGWaSMMP3sa7vlHX6H271ylzNEkn2+OCIWkkhQLC2Tub1XqOnsa4+WUXZm8tNyCC3861VETHHykJgsT2+nWktoHQyszttVthGOSc9TitF7K3+wpcG8CxTP8q79rbFySD6j9av6XbT3ceoNb26OgHmLISBhcEKOnHHr3FTfQEtTN+zDezsivKw3tJt4Hrj88c0q+TbN5qoHKD7vAPBo1Bvs7C38xY3wpCkg7snoxz0+lUWtgb94g0k7o7EMhwQAM5542/WiMe4nJdDTiuZXDIEDMZBJETgBQR1z25GDT/OkXVR5UQgUSCVGTBZO2847c9O+Pxqhtlv1Qp5zXLjBZVw20e5OMZ9K3RZLeaHObGF7dZpB5n73eQiLljnsMkjHvTskF7nZfDKxvIL+5lublJoJFfyljXCrhtuR9QK9H3eXxXM+AEVtOaZU2qqrAOc5Kj5v1OPwrqGGOSK76MWoK5yVHebFQg8LyPWn54qLIB+TGPanDkVqRYgvbkQwsw6jtXAXzKLqWSUoJJMsqk8MR/XvXcahaGWCRkBL4yADXDtbGexuftiYuJDnyj14Hb+VY1H0NYJW0MfTNaEeuQxwowTa2/HQGvV7J/OX7RyFkUEAmvI9OVLO9wi7zIfmZxyo9B7103iHxGNLtILe3yFxgnOeKUZJK5UouVkdrPqNrASJJkBHXnpUA1m0P3ZAa8yi1hLht8hHze3WmXN2EUlT9AGrP6w09i/q6semSa3B0RgW+tVZ9XgQlmLGTsM8V5FNqExm3I7qVHTsaemqzkDcxB6n1qnWTEqJ6nb61umVnI5FWX1OIH7wFeSLq7xyZ3NirX/CQkcEn8qFNMHC3QyQnOG5Oa1dPh34B4NLY2a3JUgZziul0/SNqZXn8Ke5CKaW4SPrzTvMRPlI+YVonT5DNjBAqnc6ZMXIAOD3NUkhO4kTK4ypziracFSOBUEWnvbp796Y3mRtjqKYtTct5lGAK17KRTtHU+lcrbuT+H8q6DSyW4J5q4oUjdjwXBx26VKyhhg/hUcPTkYqUkheaogry7myPTvVdnKt8w5z17VeGGGetMOGbbgYxzSKKnmM2AgLE9KeyquPMfDE9u1JIixhnjOD0qNYl+QSB88c9qWwXJLht8R2HIH5mp18sbGiGBjkVHvHm7MbjjPAqRCMsMYNMkdKizRlJUVlbqrDINcP4q+HFjqwMti32WfO7CkhWPviu0HmCXBwUIz+NTK2OKlxTLhUlDY8LvfCup6OrwXok+wMwZ5Ik3Zxx9cewNQ2Ynt3ultZDCCwzBLHhhnpt55GO3avfOGBDLkVk33h7Trtt7QiOQHcGTjn6dD+IrnlQb2NlWg91b0PGk8OCC5ESXQdpl3F5Y9hU/wCyVB4PTbxS6jafaIVtodOS3hhiWEee+BvJyTyeSeT3rv734eW81zJKLl3ifBEP3NreoK/4Vnt8OpVjLSX07sCGBe5+UMDwcFO1ZOlO+xSqQ6M4Ufubj7HeWCuDtcMsvmJGcYLY7jrx61q6TpMgFnptiC0UjvJCoY/vyWzukXsinn3wAK7OHwRNIVa7vYguOWCmRm9znA/Q10ujaPp+jCQ2aM1xLjzbiVi0knpknt7DAHpWkKDv72hnKr/LuaGkWMemabb2cRLLEuCx6sepJ9ycmrLYNQGcD2qRWB75rrsYWsKqAHKgAHqBT0zj5gM0ADrTh0psTY2VS8TKpwSMA+lcTqOlyxMGkyzbG+ZiTz2rt5HCIWNcx4pvoLe18yZ/3gOVHcVlUWhpSbOCv0Wyu1lud7oOnPX61zuuap9tnJwwGcgGrGu66txKwUk9sGsKGN5pcc81zt6HRGOty7DO0UeTyT6VIt0z8dx0GamWzEcePTms65DCbKjHsKz6mhaknOAMYJ64qMMM5yaqnMYznJJpVnGOBjiiwXLhhMp+Rsf41Vlt5VfAbNPEhTG4kZ9O9Nkcs5O5qEwOx8O/LxjIzXe6d90Ad+tcJozBVXB9811tncfKBnHSupHMdLHbqcFu9OezRsZA4qlbXOQBnPHWrsVwsgIHJHbpVJktMpXdkgHArFurHc4ZeM11gUMMdKpXsR3HywCeNxPAx/jVpCvY5y3tWVj3x0rbsocSLiMIMcnOc1O9mPkKr9TV4JHHGM8EnH400hNkqDFK/ftxS8cUh5p7kgPu5qIHD9OMc0oJXIxlTRvC/dHHqaQEMpjU4flT296YVOVGcgdfSpm2zIR2FKi7FCjkCmMSNfmcquM96Xjfu5OBtp7nKkZ/KmrgqSeQKBCE8cGh2UYBOCelVjJKJdu35OxFSGHzZcvkGMfL+PegHpqThueO9PzxUKAYG5ufan/Q/nQMcDyO1OcLIpVgGB656VDORtGBzng0988Z49qLXExkxHyIuApNQrhmYHOF4OPWqzSyJP8AvT8uePpVi1UmJlJyWPXGaT7Idh7W7mPMbAk9mpi284PofbpVuOMK+7OcDGfSobyRgwUZ2nuKA3Hxs8ZCyDj1q1VIMqqAzFj1+lXFxgUyWVNTbbbMfSvJ/Hk008MRUkqVxxXr1ygkiZT3Fed6to8sc0i7d8Ddj2rGozWkeTQ2zly0n3mPArodKthGFD961JtJETE9gcU9YPK4x0AOK5ZO+50rTYJYlCBaw9QtwJMgYNbhlyD3wazrrEgzmpKMWVMdelQvHhs5yD+lWpyBuPGKgkQ7cqOcZq7aEt6leRzuA3deKFbAG48/hUqQrISW647UxwYmKcHHtmla41pudbp8hQAnoa3oLkgjDVy0cpGADzWjZTnPWuhIwbOysbnO3Jxiti0m5yCMmuQs5XJ+Xmt+wlWMLvPP86pAzpI5PlLEngZqldXcyR+d9jeSFcHKkE/lVmGZQuMFmYcYFUYru6giitJ7OSUE7HZTng55ArRGTuXvPnLwiO1Zozy7lgMVMtxDPL5YP7xOSAemKqJLM0qyGNooFBRt5HPQdv61YtILVGka1RQTjc6/xH+tNMktjHTFNLCnH1J5xVdFUEspJzxnOaYDwfnxSYXftbkelKq/Nz6U1olOVf5g3P8AhigBX2DaoADewo7cc1FbTxXIYwsHKkqfUGgpKZwySYXHK44PvRoA8k5wACaa5EasCM4644ApqFwZCwAHTNRPcqkgRYmfjlsjFAFpCu0BTyaQjIBOR2qJW344246c806dyNzckAZoGLLIkCmSRgOMknoBTIrpXVXU7lIyMdKybpzcPmVWaLGdo4Jq7pcTBgAf3WBhSOg9KLgTtPumT5hkHJBqw/lyHej8+1Q3cccCGaBUDxnketRW93HIC0cbKx7dqAHzRiSHlcN/Oq1vPLbI6KuTnOfatBFOAWBz1pTGDzgc8EUml1ApLqEgf5lyPYVHc6ij4zvUA9BV37MvYVXjso2kyw4DUWsA+zS4mVHlGwDpjqRV5nKEFhhfWq13KVkCKSFx2pzyeYY1B+ppisWwQRwetZ2qRBoG4z3rRAwABUVym9GHtUSVxxepxN/Zr9nVwPXPtxWJdRY5UcAYz6iuxuoNu5WPysPyrnZIcl4ujA8e4rlcdTqUjnJUZh061RlhbJAFdBJF2x7g1CsaluBS5SrmHHpbSR8/yqrc2LQKUCkkDj1rtIY8ofl/ContA8q7k9qqxLZwlvbNkBxhi2c44FW57RfM5kIPtzXUXmkFyUgjAH973rKfSbhmO5Gzn1xSsCfYqrC2VPatOwti8vTgVatrPzMYHTnFbdhYHepArdGTEsrN1QN/Bn8RWtrsUFlo1tMjhZXZQnqxPb8q0NNgjL7JV+bGAaz7nTWLTiaeOSWOMrbeYflTPf8A3h6VSJlrsa0IeNbaKTehm6EjO0gZxVO9ux9qtwTKfs0xErx8fh75zVaVry4+zGe6WO0t0zK0Tcvx1yOnWuV17V5JbwKhVEWEMI933kPQE4ySafPZ2Js+p3Wlaw2o3MyW9uVsl+7M+cvnrwa2ooxHEBGOB0rh7fxXD9l8h1W3CsIlmQ/KAQMHnp3/ACrr9IuGnsY2mdXkAwzAghv9oY7Hr+NOMr7CkrFo5JIPSkRApwowPapCBjNQu47HmqENLBnIyPSk37CAxBA45pNiIrMHIz8xzzUaCKdMJKPNHI5oYFgKFJwMN3IHWmBgre1Upd1w21pGSRD1Q+n9KmjVzxJijRASZTJYnIPalB4yF49h1qEZWUjqOpGalCrIApyuenrR6jBQDIcrg+lLs3iSMZG7vToX2SbG5yM5z1pi5ViwPGc8+lAjKuYY4pAoUuoOCTV+1VI0Gz7jkY74qWaFJ1YAjcf0qJbWSLCROSvfvSa1Hcr30MqGT5gdx7UlghQ/N+FTLZz/AGncZMxnqpH61eESonTJp6vcVwRfk5PGPzpdozz9KkH3RSbc56UBcTYFbg1GY9jlgMhutSjH8Jz9Oacy7lxkj3FJO+oFdkjkIG7BHApk0QH3TnnNW/LX0pQi46UCuCn5RUM0m3naT9Kmz61BNnGc5oGjLvcuMkcVz1yojuo3YjGcE1v3r/Kcda5jUpAOC3K9axkjaJSu8K5BOO1VbWRfNI6iob65DDIJqhHclZQRUI03OntMAYIPNSu0aSAsNxxnb7VmWt0MA7sHHBq0LiMRtwTlsfQUMRpBo/s7uoyScAd81TaCUMdrxKDzjArIvLhUlJikzvHPzdD61ROq7DtfcGHoCc1LQ0dxaWUKME3Ddtz0z+FaSWrJF5gwCvarVpFDkmRdhGA2RyPrV8xRiJzxsPO4V0Wsc7kYs9zJEQwjbcAcEDnp3z2rDv8AW2MEbXA2MzrHktyM8ceua0teuIY7fzYrnzP4QpXNcRq1zF5v7qPCzLtbLfKGzwfY8Ur9CraHY+VcRaFLcWr/AGiVIisdvtBbnt9cVwV3DbNp9/Pp/wC8fYgLNlDnBDDaepBHardlquoWdi6XV2sK87GPLNjgY55re8LWtvrVzcSzskfkIoKdckg/Pz1/xqGtblXSOM0SX7LciaCFQ6xMjwqSTMD/AHlP8Q/rW5qmrxXun6RpenJJDK427eVYYwuTjqc12Nr4TFvePdRzK7uwOTGFwo6Dj6VsPp9iwhnezV7hCVVwoLqT1Oe1aRTe5nddCzpdq2n6ZBbvK0zRIAXbqxpY44mjE0g+ZvU9DVrgqQenSoCrCIqqhgT0arIRXuN0LMERnTG7A5IqNrVJVWQxLuHOTyasKGDku2WP8qlGMEAdBxTKIraABpDt256Y/nU5jAU44pI1JGdx4PbvTndQR83fkGgkoywy7g44GfxxTlPlTrnLAjgEdKmnkGRjtUQZZOpHAA/Cgeg+UAupUlSpJIx1pqTCQnaeRxxUiABeMUAfJu2jbnJA70XAaAByFw56mlnBMDLkru6sM8UkrrsLoMjHH1qRGJRfXHNCD0GWcTQQbDK8hHOXPNTt19c03J3Y79aXcc8daErA2CtgEUnU8mjnoOBSjAFAEcFukTyunWQ5bJ4z61MSRxSZz3oPWgCQE4p3Woy4XGetPzx0pCEcVWlztIqyfmHHSoJhxxxQCMO9O08nj+VcvqS/O56jtXXXkXBzXN30LbmGPoazkbRZyl4CAQorMlZl5roby3KgnHNZkkJI6fpWZpuVFvCuMHkdauW96SjFyG444rMuYzG+7HFMimLk7QMAdhRa4rmlK0RRVxhzye9VcMOjAD6ZpJGWReOCvqaYxdj+7GF6Uh+p6/cXsU+pXaMksTwALIWQ7XRuhHqR6Uado91Y2s1vHcKUkl3KuCQox79M+lbN7ZQ3MsE0rOrQNuUo2M+x9RU3lKWLKecYPvW3Kc9zgPEFhd29r9qhVLq2ycrGDnv0/HvXNGEXwVJl+zRIuSrDnnj8etes+VHZ2TwglkIIVT79v1rm77w7ZwRt5zXEkJwWDtkrjpggf4mk7otO5xMqXJWIQxpPLJEYhG6kMg4yxx0HTitfQLW70AWttcLaRi7jESZfDNtGTI/XnnP6Vtw6NJpVqtxZsLmSRwNrMRuQ9QDjr9avtoK3hQ3DS7IhiEEDcoIwRu+vNJRFJ32N+ByIo1Y7gVGHQ5De9ToNidOOtUtO0+HTrSK2t94ijG1VLE1cJ2/KOtaozYMQDkkgA9qoxCZriVp5AY0bdEF4wMdD61ZkfYG3KCB6Hmoy53bXT5D6dKeoAQ8qhhtGeRjnNRxudxyeCO1OiXymZICBGfXsakYgIVC5boOMfjQMqhXScvvfa3OKZcTLuO+dY1B5yMsfoKtvlU/rUbLC23aBv9etAIrQb5JAx8wwD7zOME1bdQ7OPLxGoBVlbO72qVwfujkelNiCpnjAzQDG2dsv2ZcuxJyc56U2PzGQAcLk5J6n2pyojPIFLqynnnj608qsQPJ5oC7buxhXA204Nj69qWIl0y3UmkAxKhPr3oAr3ly8JBVWcnjC1NauZolbpkdO9TsnV8ZbtnpUVvHsPHAzn2FF+giXvTTjNB3ZPApFBO7jPegBwakLdSO1NbIHHWpFG2EEDtzTAVBtjLkfMeeaasrsmSQKUESRbUOWB71UDN9oKbSRzz70gSuX1bJx7UrrxUcJxuwM9qmbkUgKF1GCCcVh3sKk9K6OcfLz0rF1NNq5XqeAPWoki4s525gBB7iqT2YwcLzWw8bAkN1HXFNEYfIGaixocpf2G5WJO0Y49Kx7WzXc204GcehNd1eWhaEgDNc3LZz7mZFKsD2pAjIkj2Fic9OQasRxOFG4c1ZkgdgpVCvHRvWpmgwfmDE/Wk0NaansxB3juMU0rhyyk5/u9jUtBroOe5ERJu3fKBjvUaTW80skCyI8qcuoPIz61gNf3L3DRmU7GuHixgcKBn+lV7VP7O8TRtC7P9uc+YrnIT5P4cYx90cfWpTux2Z1H2ZN6Mvy7Ow4BqfpQetNzVCA8tnsKYH3NlMMOlMydxBPGcUgUAtjgnGfemAy4QKkjs+dxAGOxpsTltwYlsfL9KDGDIrFmI5G3PH1+tR7BFFKy5yTnk1KYyzsywVRxnJptwyxRltwUDqSabYSNIrFjk5Ip04BXBAIJwRTQNWdgPzLnGR1pdokIYrjFOQYXiq8EjYYds07ATITjJ6dvU0/LbgrLg44qvMTgYOOc09HaVRuPPtR1ESLgEkD8RSqRvOeR2pIUCooGSAe5qDcxmbJOAOBTtcLXLB2hmweDzTAu5uTj0pIzyR6U4AEUgBdwUYORTiMdqGG3pSrwAKABTwaADuOwgeppp4OKVThf+BUABXqQ2TQp2DpweoqTv8AhTXAx9aAGpjDtGuG96cmT1AB9aEJL8+lSAcUNAKFwc0tFFIRDKOC1Y+onjJ5IINbU33G+lYd4c5FTIuJSuNu3P8AebNVwCc44IHINRyyMEI44OaYrsY2bPIqGtTQsEYj5BIqCWBUQnA3GrFixbJNNuP3nLf3qGgT1M17JZlzj5yetRzaRIWyC3T0rrbO1iKAlea1khjx90UKIOVj/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Egg of",
"    <em>",
"     Echinostoma",
"    </em>",
"    spp in an unstained wet mount of stool.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Echinostomiasis. Available at:",
"     <a href=\"file://dpd.cdc.gov/dpdx/html/Echinostomiasis.htm\" target=\"_blank\">",
"      file://dpd.cdc.gov/dpdx/html/Echinostomiasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_50_27439=[""].join("\n");
var outline_f26_50_27439=null;
              